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INTRODUCTION 
 In the last few decades, much research has been aimed at prevention and 
treatment of disease with a significant degree of success. Treatment of an acute 
disease or a chronic illness has been accomplished by administering various 
pharmaceutical dosage forms like tablets, capsules, creams ointments, syrups, 
suppositories and injectables to the patients. Even though these dosage form ensure a 
prompt release of drug, it is necessary to administer these conventional dosage form 
several times a day to maintain the drug concentration within the therapeutically 
effective range for the treatment. 
 In the past three decades several advancement in drug delivery system have 
been made. As a result new techniques have been developed as delivery systems. 
These techniques are capable of controlling the rate of drug, delivery. Sustaining the 
duration of therapeutic activity and targeting the delivery of a drug to a tissues. 
New carrier system has been designed to procure site-specific 
pharmacological action drug or controlled release of drug or prolonged duration of 
action of the drug, thus enhancing efficacy while diminishing undesirable side effects. 
Novel drug delivery system are being developed rapidly so as to overcome the 
limitations of conventional dosage form. 
Improving the effectiveness of an existing drug by optimizing the delivery and 
dosage, minimizing the side effect and finding the therapeutic uses may be a better 
investment and more effective for patients than creating a brand new drug. The 
objective is to encourage research to develop technologies for targeted controlled and 
sustained delivery of drug with reduced side effects that efficiently deliver drugs into 
cells. 
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NOVEL DRUG DELIVERY SYSTEM 
 The goal of any drug delivery system is to provide a therapeutic amount of 
drug to proper site in the body to maintain the desired drug concentration. That is the 
drug delivery system should deliver the drug at a rate dedicated by the needs of the 
body over a specified period of treatment. 
 The development of several novel drug delivery system of medication 
provides a number of therapeutic benefits. The novel drug delivery system may be 
broadly grouped into two types namely: 
• Spatial drug delivery system and  
• Temporal drug delivery system 
1. Spatial drug delivery system: 
It relates to targeting a drug to a specific organ or tissue. 
2. Temporal drug delivery system: 
It relates to controlling the rate of drug delivery to the target tissue 
Present scenario and future of NDDS: 
In India major thrust area of research and development for NDDS are: 
• Liposomes 
• Niosomes 
• Nanoparticles 
• Transdermal drug delivery 
• Implants 
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• Oral system 
• Microencapsulation or microcapsules 
• Polymer in drug delivery 
Novel drug delivery system can be broadly divided into two classes. They are as 
follows 
 Sustained release drug delivery system  
 Controlled release drug delivery system 
Sustained release drug delivery system includes any drug delivery system that 
releases the drug over an extended period of time. If the system is successful in 
maintaining constant drug level in the drug or target tissue, it is considered as a 
controlled release system. If it extends only the duration of action over the 
conventional delivery system, it is considered as prolonged release system 
SUSTAINED RELEASE DRUG DELIVERY SYSTEM 
Sustained release drug delivery system is described as a pharmacological 
dosage form, formulated to retard the release of a therapeutic agent such that its 
appearance in the systemic circulation is delayed and / or prolonged and its plasma 
profile is sustained in duration. The onset of its pharmacological action is often 
delayed and its duration of the therapeutic effect is extended and therefore the action 
is sustained e.g. coated granules. 
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CONTROLLED RELEASE DRUG DELIVERY SYSTEM 
Controlled release drug delivery drug delivery system has a meaning that goes 
beyond the scope of sustained drug action it implies a predictability and 
reproducibility in the release kinetics. The release of drug from a controlled release 
drug delivery system proceeds at a rate profile that is not only predictable kinetically 
but also reproducible from one unit to another. 
 The improvement in drug therapy is represented by several potential 
advantages of controlled release system. 
1. Avoid repeated administration and minimize the patient compliance problems 
2. Minimize drug accumulation with chronic dosing.  
3. Minimize local and systemic side effects. 
4. Improve efficiency in treatment by 
a. Improving the bioavailability of some drugs. 
b. Reducing the fluctuation in drug concentration in blood level. 
5. Economical 
a. Average cost of treatment over an extended period of time is less. 
b. Decrease in nursing time/hospitalization. 
The following drugs are not suitable for formulating a sustained release medication. 
 .Drugs with long biological half-life (more than 40 hours) e.g. digitoxin. 
 Drugs with narrow requirement of absorption. 
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 Drugs with very short biological half-life (less than 1 hour) e.g. penicillin. 
 Drugs which are very insoluble and whose availability is controlled by 
dissolution e.g. griseofulvin. 
Controlled release drug system can be classified into four categories 
1. Rate pre-programmed drug delivery system e.g. Implants. 
2. Activation - modulated drug delivery system e.g. osmotic pump. 
3. Feedback – regulated drug delivery system e.g. glucose triggered insulin 
delivery system. 
4. Site – targeting drug delivery system e.g. niosomes, liposomes. 
1. Rate pre-programmed drug delivery system 
 In this system the release of drug molecules from the dosage form has been 
pre-programmed at specific rate profiles. This was achieved by system designing 
which controls the molecular diffusion of drug molecules in and/or across the barrier 
medium within or surrounding the delivery system. Examples: Implants, Transdermal 
system. 
2. Activation modulated drug delivery system 
 The release of drug molecule from this delivery system is activated by some 
physical, chemical, biochemical process and/or activated by the energy supplied 
externally. The rate of drug release is then controlled by regulating the process 
applied or energy input. 
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 Based on the nature of the process applied or type of energy used, these 
activation modulated drug delivery system can be classified into three categories. 
1. Physical: e.g. osmotic pressure activated drug delivery system – osmotic 
pump, iontophoresis activated drug delivery system. 
2. Chemical: e.g. pH activated drug delivery system. 
3. Biochemical: e.g. enzyme activated drug delivery system. 
3. Feedback-regulated drug delivery system 
 The release of drug molecule from the delivery system is activated by a 
triggering agent, such as biochemical substance in the body and regulated by its 
concentration via some feedback mechanism. 
e.g. bio responsive drug delivery system and glucose triggered Insulin delivery 
system. 
4. Site targeting drug delivery system 
 In this system the drug molecule are circumventing the other tissues and 
moving towards the specific diseased site and get released. This will enhance the 
therapeutic effectiveness and reduces the toxicity to other healthy tissues and improve 
the treatment spectrum e.g. niosomes, liposomes and microspheres. 
 Niosomes and liposomes are unilamellar or multilamellar vesicles wherein 
aqueous solution is enclosed in highly ordered bilayer. They are capable of entrapping 
hydrophillic and hydrophobic drug molecules either in the aqueous layer or in lipid 
materials. They are osmotically active, stable, biodegradable, biocompatible and non-
immunogenic. 
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MERITS OF NOVEL DRUG DELIVERY SYSTEM 
1. Improved treatment of many chronic illness when symptom breaks through 
occurs when the plasma level of drug drops below the minimum effective 
level e.g. patients suffering from bronchial asthma and arthritis. 
2. Increased bioavailability 
3. Reduction in the incidence and severity of onto wards systemic side effects 
related to high peak plasma drug concentration. 
4. Reduction in the total amount of drug administration over the period of drug 
treatment, this contributes to reduced incidence of systemic and local side 
effects. 
5. Protection from first pass metabolism and gastrointestinal tract degradation. 
6. Improved patient compliance resulting from the reduction in the number and 
frequency of doses required to maintain the desired therapeutic responses. 
7. Targeting the drug molecules towards the tissue or organ reduces the toxicity 
to normal tissues. 
8. Biocompatibility. 
9. Versatile and pH dependent system release the drug whenever the body 
demands. 
10. Maintenance of therapeutic action of a drug during overnight 
11. Economic savings are claimed to be made from better disease management 
achieved with this system. 
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LIMITATIONS OF NOVEL DRUG DELIVERY SYSTEM 
 Through there are so many advantages in this system there are few factors that 
limits the usage. The following are some of the disadvantages 
1. Variable physiological factors such as gastrointestinal pH, enzymes, activities, 
gastric and intestinal factors transit rates, find the severity of patient’s disease 
which influences drug bioavailability from conventional dosage forms. All he 
above factors may also interfere with the absorption of drug from the system. 
2. Drug having biological half-life of 1 hour or less are difficult to formulate or 
sustained release formulations. The high rate of elimination of such drugs 
from the body needs an extremely large maintenance dose which provides 8 to 
12 hours of continuous therapy. 
3. If it is once administered it may be difficult to stop the therapy for reasons of 
toxicity or any other. 
4. It may unwise to include potent drugs in such system. 
5. The product which tends to remain intact may become lodged at some sites. If 
this occurs slow release of drug from the dosage form may produce a high 
localised concentration of drug which causes local irritation or some side 
effects. 
6. These products normally contain a large amount of drug. There is a possibility 
of unsafe over dosage. If the product is improperly made. 
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NIOSOMES – A REVIEW 
Niosomes are one of the novel drug delivery system. Niosomes are unilamillar 
vesicles where in an aqueous solution is enclosed in highly ordered bilayer system. 
Both hydrophilic and lipophilic drugs can be entrapped either in aqueous layer or in 
vesicular membrane made up of lipid material 
Because of the presence of the non-ionic surfactant and the lipid in niosomal 
formulation, drug molecule entrapped in niosomal drug molecule entrapped in 
niosomal drug delivery system is released slowly and the duration of action is 
prolonged. This concept is very useful for targeting drug for the treatment of cancer, 
parasitic and viral diseases. Niosomes have similar physical properties as liposomes 
and also behave as liposomes in vivo. 
In the early 1960, Bangham et al. described liposomes, the phospholipid 
carrier as the drug carriers. Liposomes are prepared from phospholipids and require 
special conditions for handling and storage as they are liable to oxidation. Liposomes 
exhibits chemical instability and its physical properties vary with surface charge of 
membrane which also makes it relatively toxic 
Concept of niosomes as carrier to deliver drugs to target organs and modify 
drug deposition may be similar to that of liposomes which suffer from certain 
disadvantages. The following are some the disadvantages of liposomes. 
 Liposomes formulations are expensive. 
 Liposomes are chemically unstable because of their predisposition to 
oxidative degradation. 
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 Purity of the natural phospholipids is another criterion that may affect 
the release of release of drug from liposomal drug delivery system. 
Alternatives to phospholipids are thus of interest from technical view point 
and could also allow a wider study of the influence of chemical composition on the 
biological fate of vesicles. 
Many synthetic amphiphiles form vesicles but as most of them are ionic and 
relatively toxic they are generally unsuitable for use as drug carriers. Niosomes are 
vesicles mainly consisting of non-ionic surfactants and lipid like cholesterol. 
 One of the reasons for preparing niosomes is the assumed higher chemical 
stability of surfactants than that of phospholipids, which are used in the preparation of 
liposomes. Due to the presence of ester bonds, phospholipids are easily hydrolysed. 
This can lead to phosphoryl migration at low pH. 
 Another type of degradation in liposomes is peroxidation of unsaturated 
phospholipids. In order to avoid peroxidation process, vesicles are often stored under 
nitrogen atmosphere. Unreliable reproducibility arising from use of lecithins in 
liposomes leads to additional problems and has lead scientists to search vesicles 
prepared from other material, such as non-ionic surfactants. 
SALIENT FEARTURES 
1. Niosomes entrap solute in a manner analogous to liposomes. 
2. Niosomes are osomotically active and stable as well as they increase the 
stability of the entrapped drug. 
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3. Niosomes are more stable then the liposomes, because the phospholipids 
present in liposomes gets easily oxidised. 
4. Handling and storage of surfactants require no special condition. 
5. Niosomes possess an infrastructure consisting of hydrophobic and 
hydrophilic moieties together and as a result can accommodate drug 
molecules with a wide range of solubilities. 
6. Niosomes improves oral bioavailability of poorly absorbed drugs and 
enhance skin penetration of drugs. 
7. Niosomes exhibit flexibility in their structural characteristics (composition, 
fluidity, size) and can be designed according to the desired situation. 
8. They allow their surface for attachment of hydrophilic group and can 
incorporate hydrophilic moieties in bilayer to bring about changes in the in-
vivo behaviour of niosomes. 
9. Niosomes dispersion in aqueous phase can be emulsified in non-aqueous 
phase to regulate delivery rate of drug for eternal application. 
10. Niosomal surfactants are biodegradable, biocompatible and non-
immunogenic. 
11. Niosomes improve the therapeutic performance of the drug molecules by 
delayed clearance from the circulation and also it protects the drug from 
biological environment. 
12. Niosomes are capable of encapsulating large quantities of material in 
relatively smaller volumes of vesicles.  
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NIOSOMAL DRUG DELIVERY 
 In recent years niosomes received great attention as potential drug delivery 
systems for different routes of administration parentally as well as orally. A 
tremendous work have been done to formulate drugs in niosomes which serve as 
carries for delivery of drugs, antigens, hormones and other bioactive agents. 
 Niosomes are unilamellar or multilamellar vesicles wherein aqueous solution 
is enclosed in highly ordered bilayer structures made up of non-ionic surfactant with 
or without cholesterol and dicetyl phosphate and exhibit non-toxic, biodegradable, 
non-immunogenic and of suitable size and shape to accommodate a variety of 
substances. 
 Niosomes are formed by mixing phospholipids, non-ionic surfactant with 
aqueous medium. They are microscopic structures consisting of one or more 
concentric lipid bilayers surrounding aqueous compartments. A schematic diagram of 
a niosome, formed with non-ionic surfactant and cholesterol is shown in figure1 
The surfactant and cholesterol form a variety of aggregates from micelles to 
large vesicles, which can be used as vehicles for drug delivery. 
This is in accordance with the observation that a cone shaped and wedge shaped non-
ionic surfactant and cholesterol to form bilayer membranes. These include carriers in 
oncology for delivery of anti parasitic agent, cosmetic formulations and as topical 
vesicles. 
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Figure 1. 
 
Niosomes improves the therapeutic performance of the drug molecules by 
delayed clearance from the circular, protection the drug from biological environment. 
Niosomal formulations have been extensively studied to enhance the efficiency of the 
delivered drug via several routes of administration. In the last few years, many studies 
have also reported that topical delivery of niosomally encapsulated drugs may offer 
several advantages over conventional formulation such as decreased side effects and 
the control of the rate and extent of drug release into the skin layers. 
Niosomes as a carrier for controlled drug delivery 
Niosomes, the non ionic surfactant vesicles reported recently can entrap both 
hydrophilic drugs, either in aqueous layer or in vesicular membrane made up of lipid 
materials. It is reported to attain better stability than liposomes. It can prolong the 
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circulation of the entrapped drugs. Because of the presence of non-ionic surfactant 
wiped the lipid, there is better targeting of drugs to turnover, liver and brain. It may 
prove very useful for targeting the drugs for targeting cancer parasitic, viral and other 
microbial diseases more effectively. 
Sources of niosomes 
 Glycerol containing phospholipids are the most commonly used component of 
niosomes formulation and represent more than 50% of the weight of lipids present in 
biological membranes. The most common phospholipids isphosphatidyl choline. It 
consists of a glycerol bridge linked to a pair of hydrophobic acyl hydrocarbon chains 
with a hydrophilic polar head group. phosphatidyl choline also known as lecithin can 
be derived from natural source. They are readily extracted from egg yolk and 
soyabean but less readily from bovine heart and spinal cord. The phospholipids are 
the major constituent of many cell membranes. They are often used as the principal 
phospholipids in noisome for a wide range of application both because of low cost 
relative to other phospholipids, the natural chargeand chemical inertness. The other 
phospholipids such as phosphatidyl serine, phosphatidyl ethanolamine, phosphatidyl 
glycerol, phosphatidyl inositol, phosphatidic acid and synthetic phospholipids such as 
dipalmitoylphosphatidyl choline, distearylphosphatidylcholine, dipalmitoyl serine and 
cholesterol were also used in the preparation of niosomes. Some of the structure of 
phospholipids is shown in figgure2 
Niosomes have been prepared from several classes of nonionic surfactants e.g. 
polyglycerol alkyl ether, Glucosyldialkyl ether, crown ether, polyoxyethylene alkyl 
ether, ester linked surfactants, Brij and a series of spans and tweens 
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Figure 2 
.   
 
NIOSOMES FORMATION 
 Lipids capable of forming niosomes exhibit a dual chemical nature. Their head 
groups are hydrophilic and their fatty acyl chains are hydrophybic. It has been 
estimated that each zwitter ionic head groups of phosphatid33lycholine has bound on 
the order of 15 molecules of water, which explains its preference for their water 
phase. The hydrocarbon fatty acid chains on the other hand, vastly prefer each other 
company to that of water. This phenomenon can be understood in quantitative terms 
by considering the critical micelle concentration of phosphatidyl choline in water. 
 The critical micelle concentration is defined as the concentration of the lipid in 
water above which lipid forms micelles or bilayer structure rather than remaining in 
solutions as monomers. The large free energy charge between water and a 
hydrophobic environment explains the overwhelming preference of typical to 
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assemble in bilayer structure excluding water as much as possible as much from the 
hydrophobic core in order to achieve the lowest free energy level and hence the 
highest stability for the aggregate structure. 
 It is clear from the thermodynamic consideration that bilayer structure do not 
exist as such in the absence of water because it provides the driving force for lipid 
configuration. 
TYPES OF NIOSOMES 
Generally, the niosomes have been classified as a function of the number of 
bilayer (e.g. MLVs, SULVs) or as a function of size (e.g. LULVs, SULVs) or a 
function of the method of preparation (e.g. REV – Reverse Phase Evaporation, DRV – 
Dried Reconstituted vesicles). 
1. Multilamellar Vesicles (MLVs)- 1000 to 5000nm 
2. Larger Unilamellar Vesicles (LULVs)-100 to 1000nm 
3. Small Unilamellar Vesicles(SULVs)-25 to 500 nm 
 Multilamellar vesicles 
 It consists of number of bilayer surrounding the aqueous compartment 
separately. MLVs are the most widely studied type of niosomes. It is simple to make 
and they are mechanically stable upon storage for longer period of time. These vesicle 
are highly suited as drug carrier for lipophilic compounds. 
 Larger Unilamellar Vesicles 
 Niosomes of this type have a high aqueous lipid compartment ratio. So the 
larger volume of bioactive material can be entrapped with a very economical use of 
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membrane lipids. These provides a number of advantages as compared to MLVs, 
including high encapsulation of water soluble drugs, economy of lipid and 
reproducible drug release rates. Because of the larger size of the vesicles high 
percentage of capture can be achieved. 
 The term large unilamellar usually means any structure larger than 100nm. A 
number of techniques for producing large unilamellar vesicles have been used 
including freeze – then cycling reverse phase evaporation method, ether injection 
method and calcium induced fusion method. 
 Small unilamellar vescicles 
 These small unilamellar vesicles are mostly prepared from Multilamellar 
vesicles by sonication method, French press extrusion method or by homogenization 
method. They are thermodynamically unstable and are susceptible to aggregation and 
fusion. Their entrapped volume is small and percentage entrapment of aqueous solute 
is correspondingly low. The approximate size of small unilamellar vesicles are 25 to 
500 nm in diameter. 
PHYSICAL STATE OF VESICLES 
 Depending on the temperature, the bilayers of the vesicles are either in the 
liquid state or in gel state, the structure of bilayer is arranged in a well-ordered 
manner and in the liquid state; the structure of the bilayer is more disordered as shown 
in figure3. 
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Figure 3. 
 
METHOD OF PREPARATION OF NIOSOMES 
It depends both on the methodology used for their production and composition. 
Whatever the method, the basic reaction is same, that is hydration by the aqueous 
phase of the liquid phase either by surfactant or mixture of surfactant and cholesterol. 
METHODS OF PREPARATION OF NIOSOMES 
 Multi Lamellar Vesicles (MLVs)  
1. Thin film hydration method 
 Large Unilamellar Vesicles (LULVs) 
1. Reverse Phase Evaporation method 
2.  Calcium induced method 
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3. Dehydration / Rehydration of small Unilamellar Vesicles 
4. Detergent removal method 
 Small Unilamellar Vesicles (SULVs) 
1. Sonication method 
2. French press method  
3. Ethanol injection method  
4. Ether injection method  
5. Homogenization  
6. Dried Reconstituted Vesicles 
I. Multilamellar vesicles 
 Bangosomes popularly known as MLVs are prepared according to the method 
of Bangham et.al. Lipids are dissolved in an organic solvent in a round bottom flast. A 
thin lipid layer is formed on the inside wall of the flask by removal of the organic 
solvent by rotary evaporation at reduced pressure. 
 Multilamellar vesicles were formed spontaneously when an excess volume of 
aqueous buffer was added to this dry lipid layer. Shaking (by hand or vortex mixer) 
yields a dispersion of multilamellar vesicles. Duration and intensity of shaking, the 
presence of charge inducing agent in the bilayer, ionic strength of the aqueous 
medium and lipid concentration is important parameters influencing the size and the 
encapsulating efficiency of multilamellar vesicles. The lipids formed were 
heterogeneous both in size and number of lamella. 
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II. Large unilamellar vesicles 
 Large unilamellar vesicles provides a number of important advantages as 
compared to multilamellar vesicles including high encapsulation of water soluble 
drugs, economy of lipid and reproducible drug release rates. However large 
unilamellar vesicles are perhaps the most difficult types of niosome to produce. 
1. Reverse phase evaporation method 
 LULVs can be prepared by forming water in oil emulsion of phospholipids 
and buffer in the excess organic phase followed by the removal of organic phase 
under reduced pressure. The two phases are emulsified by sonication. The organic 
solvent is removed under vacuum and causes the phospholipid droplets to cool and 
form a viscous gel. These droplets of phospholipids merge with adjacent collapsed 
vesicles to form LULVs. The aqueous content of the collapsed droplet provides the 
medium required for suspension of newly formed niosomes. After conversion of gel 
to a homogeneous free flowing fluid,  the suspension is dialyzed in order to remove 
the last traces of solvent. This method has gained widespread use for applications that 
require high encapsulation of water soluble drug. Entrapment efficiency up to 85% 
can be obtained with this method. 
2. Calcium induced method 
 This method is used to produce unilamellar vesicles and it is of high interest 
for the present investigation. This method takes advantages of the fact that small 
vesicles aggregate in the presence of calcium and subsequently fuse. 
 In calcium induced method, the percentage of encapsulation depends on the 
concentration of lipid. In this method only 30% of encapsulation of the drug is 
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expected. The vesicles obtained will be in the size range of 200 to 1000 nm in 
diameter. Large niosomes could be produced on addition of EDTA. 
 The flocculent precipitate is obtained as a result of aggregation of the 
negatively charged vesicles by calciumcations. After incubation, the membranes fuse 
to give extended sheet of phospholipids lamella, to roll up with calcium ions as a 
driving force. On addition of EDTA, this lamella is released and subsequently formed 
LULVs. This technique has the advantage that it does not expose lipids or entrapped 
material to deleterious chemicals or physical conditions. 
3. Dehydration / rehydration of small unilamellar vesicles 
 In this method, the sonicated vesicles are mixed in an aqueous solution with 
the solute to be encapsulated and the mixture is dried under a stream of nitrogen. As 
the sample is dehydrated, the small vesicles fused to form a multilamellar film that 
effectively sandwitches the solute molecules between layers. Upon rehydration large 
vesicles are produced which have encapsulated a significant proportion of solute. The 
optimal mass ratio of lipid to solute was approximately 1:2 to 1:3. This method has 
potential application to large scale production. Since it depends only on controlled 
drying and rehydration processes and does not require extensive use of organic 
solvents, detergents or dialysis system. 
4. Detergent removal method 
 Removal of detergent from mixed micelles formed by solubilizationof dried 
lipid mixtures or formed niosomes with detergent containing aqueous phase result in 
the formation of unilamellar vesicles. This is gentle method where no strong 
mechanical force and no high temperature are applied. The preparation procedure 
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should include a step to minimise residual detergent level after niosomes formation. 
The techniques reported for the removal of detergents includes dialysis and column 
chromatography. 
III. Small unilamellar vesicles 
1. Sonication Method 
 Method for the preparation of sonicated small unilamellar vesicles have been 
reviewed by bangham and horne. The usual MLVs and SULVs formed are sonicated 
either with a bath type sonicator or a probe sonicator, under an inert atmosphere 
(usually nitrogen or argon) to get the small unilamellar vesicles. During sonication the 
multi lamellar vesicle structure is broken down and unilamellar vesicles with high 
radius of curvatures are formed. 
2. French press method 
 Dispersion of MLVs can be converted to small unilamellar vesicles by passage 
through a small orifice under high pressure. A French pressure cell was used by 
Hamilton and guo for this purpose. MLV dispersion is placed and extruded at about 
20,000 Psi at 40 C. A heterogenous population of vesicles ranging from several 
micrometers in diameter to SULVs size was formed. These niosomes are more stable 
than sonicated ones and can be used advantageously as drug delivery carriers. 
3. Ethanol injection method 
An alternative method for producing small niosomes that avoids both 
sonication and high pressure is the ethanol injection method, first described by 
batzriand koru. Lipids dissolve in ethanol are rapidly injected into an axcess of buffer 
solution or other aqueous medium through a fine needle. The force of the injection is 
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sufficient to achieve complete mixing, so that the ethanol is diluted in water and 
phospholipid molecules are dispersed evenly throughout the medium. This procedure 
can yield a high proportion of SULVs. 
4. Ether injection method 
 This method is similar in concept to ethanol injection method. This is 
introduced by Deamer and Bangham in 1976. This method provides a means of 
making small lamellar vesicles by slowly introducing a solution of lipid dissolved in 
diethyl ether into warm aquous medium. The lipid mixture is injected into aaqueous 
solution of the material to be encapsulated (using a syringe type infusion pump) at 550 
– 650 C or under reduced pressure. Subsequently the residual ether was removed 
under vacuum and it leads to the formation of single layer vesicles. 
5. Homogenization 
 Homogenization of MLVs or other lipid dispersions by high sheer 
homogenizers like the micro fluidizer produces unilamellar  vesicles. The SULVs 
formed are longer than the minimal size formed by sonication and significant amounts 
of larger particles are also presents. The size of the vesicles produced by micro 
fluidizer depends on the pressure used and on the number of passes of the preparation 
through this device and on the niosomal lipid composition. 
6. Dried Reconstituted Vesicles  
This method has been sought to disperse the solid lipid into a finely divided 
form before contact with the aqueous fluid, which will form the medium for the final 
suspension.  Freeze drying was used instead of drying the lipid and the suspension of 
SULVs are frozen and lyophilized. The dried SULVs are very highly organized into 
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membrane structures which on addition of water can be rehydrated, fused and 
resealed to form vesicles with high capture efficiency. 
METHODS OF CONTROLLING NIOSOMES SIZE 
 The vesicles size can have dramatic effect on the in vivo behaviours of 
niosomes. Therefore their size will have to be controlled with in reasonable and 
verifiable limits. Three possible approaches have been explored for achieving particle 
size distributions of niosomes. 
a) Fractionation. 
b) Homogenization 
c) Extrusion 
a. Fractionation 
 Two method have been popular for fractionating defined sized niosomes from 
a heterogeneous population namely centrifugation and size extrusion chromatography. 
Both can be used to enrich the products with the desire particles size but are limited in 
terms of the volume that can be easily handled. 
i. Centrifugation 
 Niosomes Sediment in a centrifugal field at a rate is related to size and 
density. Large niosomes composed of neutral lipids such as phosphatidyl choline can 
easily be pelleted at fairly low gravitational forces in centrifuge under proper 
conditions. The smaller niosomes will remain in the supernatant 
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ii. size extrusion chromatography 
 Column chromatography has been used for many years as an analytical 
method to measure the particle size of niosomes. 
 Preparative scale chromatography has also been applied to isolate niosomes of 
fairly homogenous sizes. This method is useful for separating small unilamellar 
vesicles from large structures. 
 Typically a column of sepharose48 is used. As the column is washed with 
buffer, larger niosomes elute in the void volume, while SULVs appear with the 
included volume. Larger pore size chromatographic media have been used in similar 
fashion to fractionate populations of larger particles. 
b. Homogenization 
 When fairly small particles are desirable, homogenization has proven to be a 
useful approach. The average particles size of niosomes dispersion can be reduced by 
passage under high pressure through a homogenizer. Microfluidizer was to generate 
vesicles in the size range of 50 – 200 nm. Conventional homogenizer and high sheer 
mixers are also used for downsizing niosomes. 
c. Extrusion 
i. capillary Pore Membrane Extrusion 
 A technique that is used for the production of defined size and narrow size 
diatributiion is based on the extrusion of heterogenous membranes under pressure. 
Polycarbonate membranes have pores of defined size normally do not bind niosomes. 
This simple technique can reduce a heterogenous population of MLVs and reverse 
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phase evaporator vesicles to a much more homogenous suspension of vesicles 
exhibiting a much more homogenous suspension of vesicles exhibiting a mean 
particle size that approaches the diameter of the pores through which they are 
ectruded. 
ii. Ceramic Extrusion 
 If the size of niosomes is greater than the membrane pore diameter pore 
diameter the pores of membranes tends to clog. The clogged membranes cannot pore 
of the membrane used to clog. The clogged membranes cannot easily be cleared 
because the filter housing configuration does not allow back-flushing. To overcome 
this limitation, ceramic membrane was used. Extrusion of unsized niosomes through 
asymmetric ceramic filter yields sied niosomes having a selected average size 
between 0.1 and 0.4 micrometer. The suspension may be alternately passes through 
the membrane is an outside to inside direction to maintain the membrane in an 
unclogged condition. The average size of niosomes may further be reduced by 
passage through similar types of ceramic filters that have been rated at smaller inner 
surface pore diameter. 
CHARACTERIZATION OF NIOSOMES 
1. Vesicle Diameter 
 Niosomes similar to liposomes assume spherical shape and its diameter can be 
determined by using light microscope, photon correlation microscopy and freeze-
fracture electron microscopy. The shape of vesicle can be confirmed by transmission 
electron microscopy. 
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2. Entrapment Efficiency 
 After preparing niosomal dispersion, unentraped drug is separated by dialysis, 
centrifugation or gel chromatography. The drug remaining entrapped in niosomes is 
determined by complete vesicular disruption using 50% n-propanol or niosomes is 
expressed as, 
 
 Entrapment efficiency can also be determined by the difference between the 
drug used for formulation and the amount dialysed or obtained in supernatant. The 
intercalation of cholesterol in bilayers decreases the entrapment volume and thus 
entrapment efficiency decreases. The entrapment efficiency increases with increase in 
concentration and lipophilicity of surfactant. 
3. Invitro release rate 
 Release of drug can be monitored by dialyzing dilute niosomal suspension 
against buffer at definite temperature and determining the drug content of dialysate. 
All the dialysis studies should be carried out in phosphate buffer (900ml, pH 7.4), 
maintained at 37.5°C at 100 r.p.m. The absorbance of the drug was measured.  
Factors affecting vesicle size, entrapment efficiency and release characteristics 
1. Drug 
• Entrapment of drug in niosome increases the vesicle size probably by 
interaction of solute with surfactant head groups, increasing the charge and 
mutual repulsion of surfactant bilayer thereby increasing vesicle size. In 
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polyoxyethylene (PEG) coated vesicle some drugs are entrapped in long Peg 
chain thus reduce the tendency to increase the size. 
• Degree of entrapment is affected by hydrophilic-lipophilic balance of a drug. 
For a series of tweens, Raja Naresh et.al reported maximum emtrapment of 
water soluble drug diclofenac sodium in hydrophilic surfactant tween 60 and 
Chandraprakash et.al reported maximum entrapment of slightly water soluble 
drug methotrexate in lipophilic methotrexate in lipophilic surfactant span 60 
2. Amount and type of surfactant 
• Mean size of niosomes increases regularly with increase in hydrophilic-
lipophilicbalance (HLB) from span 85 (HLB 1.8) to span 20 (HLB 8.6) 
because surface free energy decreases on increasing hydrophobicity of 
surfactant. 
• Linear correlation is between concentration of lipid and entrapment efficiency. 
• Phase transition temperature (Tc) of surfactant also effects entrapment 
efficiency that is, surfactant having higher Tc provides the highest entrapment. 
• Yoshioka et.al reported linear correlation between concentration of lipids and 
entrapment efficiency. Phase transition temperature Tc provides the highest 
entrapment. 
3. Cholesterol content and charge 
• Inclusion of cholesterol in niosomes increases its hydrodynamic diameter and 
entrapment efficiency. 
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• Presence of charge tends to increase the inter-lamellar distance between 
successive bilayers in Multilamellar vesicle structure and leads to grater 
overall entrapped volume 
• Vesicle size is slightly decreased as charge might increase the membrane 
curvature. 
• Presence of cholesterol in bilayer composition due to its membrane stabilizing 
activity reduces permeability and improves retention of solute. 
• Baillie et.al reported that incorporation of 50%cholesterol in surfactant 
composition reduces vesicle permeability. 
4. Method of preparation 
 Method of preparation of niosomes such as hand shaking, ether injection and 
sonication, developed on the basis of liposome production technique have been 
reviewed by Khandare et al. hand shaking method from vesicles with grater diameter 
(350 to 1300 nm) compared to those prepared by ether injection method (50 to 
1000nm). Sonication of MLVs prepared by above methods, either with probe 
sonicator or bath type sonicator from unilamellar vesicles with considerably reduced 
diameter. Increase in sonication time results in concomitant reduction in vesicle 
diameter. Hydrating the lipids helps to reduce the size of vesicles prepared by hand 
shaking method. 
Safford et al extruded the liposomal dispersion prepared by hand shaking 
method through 1000 nm. Small sized niosome can be produced by Reverse Phase 
Evaporation (REV) method. In this method emulsion of aqueous phase is organic 
solvent containing lipid is prepared by sonication, followed by evaporation of organic 
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solvent, resulting in the formation of vesicles. Micro fluidization method gives grater 
uniformity and smaller size vesicles. Parthasarathy et al prepared niosomes by trans 
membrane pHgradient drug uptake process (TmpH) or remote loading showed grater 
entrapment efficiency, better retention and slower release of drug 
Niosomes bearing 5, 6 – carboxyfluorescein prepared by either injection 
method slowed entrapment efficiency significantly higher than those prepared by 
hand shaking method or sonication. Niosomes prepared by remote loading method 
showed grater entrapment efficiency and slower release of drug. 
5. Osmotic effect 
 Addition of hypertonic salt solution to suspension of niosomes brings about 
reduction in vesicle diameter with concomitant water efflux which may be due to 
pumping out of vesicle content where as in hypotonic salt solution, there is initial 
slow release with slight swelling of vesicles probably due to inhibition of eluting fluid 
from vesicle, followed by faster release which may be due to mechanical loosening of 
vesicles under osmotic stress. 
INVITRO BEHAVIOUR OF NIOSOMES 
 In vivo niosomes have been equiactive to liposomes in improving the 
therapeutic performance of drug and distribution in body follows the pattern of their 
colloidal drug delivery systems. Although liver, lungs spleen and bone marrow are 
responsible for disposition of a major part of niosomes yet their level in liver is 
always significantly higher due to the natural vectoring process. Variation in size also 
influences the disposal of niosomes from blood. Variation in size also influences the 
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disposal of niosomes from blood. Large sized may reside in lungs and small sized 
niosomes in liver and spleen and then enter systemic circulation  
 It appears that liposomes, niosomes are also taken up by liver and break down 
substantially to release the free drug which re-enters the circulation nd maintain the 
plasma drug level. Parthesarrathy et al found that niosomes are stable in plasma. 
However non ionic surfactants in higher concentration delipidize the low density 
lipoproteins. 
 Moser et al found that niosomes bearing haemoglobin are physically stable 
with plasma protein compartment. Albumin and transferrin were identified and 
determined to absorb on vesicle without destablizing them. Erythrocytes donate 
cholesterol to niosomes particularly to cholesterol-free and cholesterol poor niosomes 
maintain their integrity in body as well as keeping them less vulnerable to 
destabilization. 
NIOSOMES INTERACTION WITH THE CELLS 
 Niosomes can interact with cells via five mechanisms. All mechanism are 
explained in brief as follows 
1. Inter membrane transfer 
 Inter membrane transfer of lipid component can take place upon close 
approach of the two phospholipid bilayers without the disruption of niosome. 
Interaction can take place between niosomes and in certain circumstances proceed to 
the extent of destroying the niosomes altogether 
. 
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2. Contact release 
 Contact release of aqueous content of niosomes occurs in which contact with 
the cell membrane causes an increase in permeability of the niosomal membrane. This 
leads to release of water soluble solutes in high concentration in the close vicinity of 
cell membrane through which these solutes may pass. This phenomenon can provide 
very effective means for introducing material into specific cells without the need for 
ingestion of the whole niosome. 
3. Adsorption  
 Adsorption of niosomes to the cells surface occurs with little or no 
internalization of either aqueous or lipid components. It may take place either as a 
result of physical attractive forces or lipid component. It may take place either as a 
result of physical attractive forces or as a result binding by specific receptor to the 
vesicle membrane. 
4. Fusion 
They may undergo fusion with plasma membrane of target cells. Close 
approach of niosomes and cell membrane can lead to fusion of the two resulting in 
complete mixing of niosomal contents into the cytoplasm. 
5. Endocytosis 
 The niosome is engulfed by cell. The lysozyme present in the cytoplasm 
degrades or digests the membrane structure of niosomes there by resulting the 
entrapped material into the medium. 
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STABILITY OF NIOSOMES 
 Three types of stability studies can be carried out in drug encapsulation 
niosomes. They are: 
• Physical stability 
• Chemical stability 
• Stability in biological fluids. 
Physical stability 
 Niosomes can change their physical characteristics in several ways 
1. Vesicle size may be changed because of aggregate formulation and fusion. 
2. Phase separation of bilayer components may occur upon the storage 
3. Leakage of encapsulated material from niosomes 
 1. Vesicle size changes upon storage of phosphatidyl choline containing 
niosomes over pharmaceutically relevant time intervals can be minimized by selection 
of charge inducing agents. Mostly negatively charged phospholipids (phosphatidyl 
glycerol) are used to stabilize the niosomes. 
 2. Phase separation can occurs when the bilayer composition changesbecause 
of chemical degradation reaction or when the bilayer goes through temperature cycles. 
Proper selection of bilayer component can be avoid these problems. Sometimes phase 
separation occurs invivo, when bilayer components are selectively drawn from the 
bilayer plasma components. If this effect is undesired, then more rigid bilayer plasma 
components must be prepared. 
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 3. When niosomal preparation are stored at various temperatures, the 
permeability of bilayer is highly dependent on the physiochemical properties of the 
bilayer and drug. 
 Three categories of drugs can be discussed 
• Highly hydrophilic, non-bilayer interacting drugs. 
• Drug with some lipophilicity. 
• Strongly lipophilic drugs. 
 In category first the presence of cholesterol in bilayer of the egg phosphatidyl 
choline niosomes dramatically reduces the permeability. Gel state bilayer 
permeability is low with or without cholesterol. Shelf life of the niosomes in aqueous 
media with proper pH might easily meet the industrial demands. The second category 
tends to be difficult in keep entrap over period of months. As long as outside sink 
condition prevail, the third category of strongly lipophilic drugs has a high affinity of 
the bilayer and drugs stay over a long period of time, independently of the state of 
bilayer. 
 In presence of hydrolysis/oxidation reaction, products can affect bilayer 
properties although lysophosphatidyl choline is known as the lipid bilayer solubilizer. 
The solubilizing effect of lysophosphatidyl choline in niosomes is neutralized by the 
presence of fatty acid in the bilayer. 
Stability of niosomes stored in freeze dried form: 
 The different types of cryoprotectant and the possible mechanism of action 
have been discussed by Crow et al and Ozer et al for niosomes stabilization. Usually 
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sugar are used as cryoprotectant. Some other types of excipients also have been 
reported to exert cycloprotective effect. A number of effects may contribute to 
cycloprotective action 
1. The formation of amorphous glass structures during the freeze drying process 
might avoid mechanical damage inflicted by the crystals. It is recommended to 
store these cakes below glass transition temperature. 
2. The sugars may interact with polar head groups of the phospholipids and 
stabilize the membrane when the bilayer stabilizing water is removed by 
sublimation. 
The proliposome concept 
 In proliposome formulations, liposomes are formed by hydrating lipids at bed 
side. The dry lipids (formation of film on the sides of the sides of the glass vessel is 
the form of freeze dried cake) are hydrated by shaking with an aqueous medium just 
before injection. 
 Another way to improve stability of lipids is by covalently cross linking the 
membrane using methods such as gluteraldehyde fixation or polymerization. The 
membrane stability is increased by imparting charge to the niosomes. 
Chemical stability 
 The stability of niosomal formulations depend on the chemical nature and 
stability of lipid components. The main bilayer component of niosomes contains drug 
and phospholipids. Hydrolysis and peroxidation are the two degradation processes 
which affects the stability of niosomal formulations. Different analytical techniques 
are available to monitor hydrolysis and oxidation. 
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Lipid hydrolysis 
 Grid et al described in number of articles, different variables influence the 
hydrolysis reaction of phosphatidyl choline. The major phospholipids in the niosome 
preparations are the charge inducing phospholipids like phosphatidyl glycerol. Apart 
from pH, other experimental conditions like temperature, ionic strength and ultra 
sonifications were reported to influence hydrolysis reaction. Many investigations 
choose the formation of lysophosphatidyl choline as a standard measure for the 
chemical stability of phospholipids. Since the presence of lysophosphatidyl choline in 
lipid bilayer enhances the permeability of niosomes. This problem can be minimized 
by using proper source of phospholipids. 
 Most of phospholipid niosomal dispersions contain unsaturated acyl chains as 
a part of their molecular structures. These chains are vulnerable to oxidative 
dehydration (lipid peroxidation). This peroxidation can occur during preparation and 
storage. Peroxidation of phospholipids produces the formation of cyclic peroxides and 
hydroperoxides and can be minimized by a number of ways. 
• Minimize use of unsaturated phospholipids. 
• Use of nitrogen or argon to minimize the exposure to oxygen. 
• Use of light resistance containers. 
• Removal of heavy metals (EDTA). 
• Use of antioxidants like tocopherol or butylatedhydroxy toluene (BHT). 
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Stability of niosomes in biological fluids 
 Stability of entrapped drug in niosomes in blood plasma have been studied for 
a decade. The instability of niosomes in plasma appears to be the results of the 
transfer of bilayer lipids to albumin and high density lipoproteins. The presence of 
cholesterol prevents this instability. 
 Generally niosomes are stable structures; Jain did not observe any gross 
morphological changes on storage for three months. Yoshioka and Florence found 
them stable in even emulsified form. Baaillie et al determined the stability in butter 
and suggested that a substantial amount of entrapped solute would be retained under 
long term storage conditions. 
Toxicity of niosomes 
 Non-ionic surfactants used in niosomes are non-toxic and no toxic effects have 
been reported so far in animal studies due to the use of niosomes as drug carrier. 
Rogerson et al. in their experiment on 70 male NMRI mice, did not report any 
fatalities that could be attributed to the preparation. The toxic side effects directly 
related to drugs are also reduced. 
Applications 
 The niosomes has a wide range of applications. 
1. The wide applicability is in the diagnosis and therapy of cancer. 
2. Most of the anti-tumour drugs are highly toxic to normal cells and have a 
narrow therapeutic range. The niosomes encapsulated anti-tumour drugs 
increases the shelf life of the drug and reduces the toxicity. 
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3. The niosomes are also used in the enzyme replacement therapy. 
4. In cosmetics, niosomes containing vitamin c prepration and sunscreen 
preprations are available. Recently sustained release niosomes containing 
insect and perfume loaded niosomes containing insect repellent and perfume 
loaded niosomes have been reported. 
5. In the agricultural field it has been attempted to prepare pesticides containing 
niosomes for sustained release and also introduce the genetic materials into the 
plant and bacterial cell using the niosomes. 
6. Niosomes can also have the applications in Physical Science.Niosomes have 
been used as the means of maintaining charge sepration in the photo catalytic 
cleavage of water. 
7. The use of niosomes for the delivery of food ingredients of offers the totally 
new technology with unique delivery opportunities. 
8. Improvement of flavour of cheese, targeted delivery of fuctional food 
ingredients, the synergistic delivery of ascorbic acid and for enhancing the 
antioxidant activity and the stabilization of vitamins in foods. 
Niosomal drug delivery is potentially applicable to many pharmacological agents for 
their action against diseases. Some of its therapeutic applications are: 
1. Targeting of bioactive agents 
a. To Reticulo Endothelial System: 
The vesicles are preferentially taken up by the cells of reticulo endothelial system. 
The uptake of niosomes by the cells is also by circulating serum factors known as 
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opsonins which mark them for clearence. Suchlocalized drug accumulation has been 
exploited in treatement of animal tumors known to metastasize to the liver and spleen 
and in parasitic infestation of the liver. 
b. To Organs Other Than Reticulo Endothelial System: 
The carrier systems can be directed to specific sites in the body by the use of 
antibodies. Immunoglobulin seems to bind quite readily to the lipid surface thus 
offering a convenient means for targeting of carrier. Many cells posses the intrinstic 
ability to recognize and bind particular carbohydrate determinants and this can be 
exploited to direct carrier systems to particular cells. 
2. Neoplasia 
 Doxorubicin, the anthracycline antibiotic with broad spectrum antitumor 
activity, shows a dose dependent irreversible cardio toxic effect. Niosomal delivery of 
this drug to mice bearing s-180 tumour increased their life span and decrease the rate 
of proliferation of sarcoma. 
 Niosomal entrapment increased the half-life of the drug, prolonged its 
circulation and altered its metabolism. Intravenous administration of methotrexate 
entrapped in niosomes to s-180 tumour bearing mice resulted in total regression of 
tumor and also higher plasma levels and slower elimination. 
3. Leishmaniasis 
 Niosomes can be used for targeting of drugs in the treatment of diseases in 
which the infecting organism resides in the organs of reticulo endothelial system. 
Leishmaniasis is such a diseases in which parasites invades cells of liver and spleen. 
The commonly prescribed drugs are antimonial which are related to arsenic and at 
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high concentration ; they damage the heart, liver and kidney but encapsulating such 
drugs in niosomes targets the drug to the infected organs and greatly reduces the dose 
needed to treat the infection and also reduces the toxicity. 
 Baillie et al reported increased drug efficacy of niosomal formulation and that 
the effect of two doses given on successive days were adequate. The study of 
antimony distribution in mice, performed by hunter et al, showed higher levels after 
intravenous administration of the carrier forms of the drug. Carter et al concluded that 
only multiple dosing with drug loaded sonicated vesicles were effective against 
parasites in liver, spleen and bone marrow while other treatments reduced parasites 
burdensin liver but either failed to effect spleen and bone marrow or were effective 
but toxic.   
4. Delivery of peptide drugs  
 Yoshioka et al investigated oral delivery of 9-desglycinamide, 8-arginine,and 
vasopressin entrapped in niosomes and the in vitro intestinal loop model reported that 
stability of peptide increased significantly. 
5. Immunological application of niosomes 
 Niosomes have been used for studying the nature of the immune response 
provoked by antigens. Brewer and Alexander has reported niosomes as potent 
adjuvants for protein antigens. Niosomes offer many advantages over other adjuvants 
in terms of immunological selectivity, low toxicity and stability.  
6. Niosomes as carrier for haemoglobin 
 Niosomes can be used as a carrier for haemoglobin. Niosomes suspension 
shows visible spectra super imposable onto that of free haemoglobin. Vesicles are 
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permeable to oxygen and the haemoglobin dissociation curve can be modified 
similarly to non-encapsulated haemoglobin. 
7. Transdermal delivery of drugs by niosomes 
 Slow penetration of drugs through skin is the major drawback of transdermal 
route of delivery. An increase in the penetration rate has been achieved by 
transdermal delivery of drug incorporated in niosomes. 
8. Niosomes in the treatment of neoplastic diseases 
I. Niosomes in the treatment of infectious diseases 
Application of niosomes as a drug carrier for anti- infectious drugs might be an 
effective therapy by increasing the selectivity of delivery and decreasing the toxicity 
of applied drugs. 
II. Niosomes encapsulated anti protozal Drugs 
Anti-malarial drugs - e.g. Primaquine 
Anti-fungalagents - e.g. Ampnotericin-B, Griseofulvin. 
Anti leishmanial agents – e.g. 5-fluoro cytosine 
III. Niosomes encapsulated anti-bacterial drugs 
E.g. Streptomycin, Gentamycin, Amoxycillin,Rifampicin,Dapsone etc. 
IV. Niosomes as carriers of antigens 
E.g. Diptheria toxoid,Tetanus toxoid, Rabies glycoprotein. 
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V. Intra pulmonary delivery 
E.g. Metaproterenol, Terbutaline, Sodium cromoglycate 
VI. Intra peritoneal administration 
E.g. Cisplatin, Cytosine, Bleomycin 
VII. Intra muscular administration 
E.g. Insulin 
VIII. Topical route of administration 
E.g. Glucocorticoids, Indomethacin, Vitamin D3 
IX. Intra ocular delivery 
E.g. Gentamycin, Amphotericin-B,Triamcinolone acetonide 
Other applications 
i. Sustained Release 
Drugs that are rapidly excreted or metabolized possess “Sawtooth” drug kinetics. This 
is undesirable especially for agents which have low therapeutic index. Experiments 
have suggested that niosomes can provide relatively constant and sustained blood 
stream levels of drug concentration. Many anti-tumour drugs are cleared from the 
blood stream very quickly, while the same agents, entrapped in niosomes, persist in 
the blood for hours. In contrast to other sustained release formulations, niosomes can 
be injected into circulation and thus serve as an intra vascular drug depot. 
 Liver acts as a depot for the drug after niosomes are taken up by the liver cells. 
Sustained release action of niosomes could be applied to drugs with low therapeutic 
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index and low water solubility. Since these could be maintained in the circulation via 
niosomal encapsulation.  
i. Topical Action 
Drug delivery through niosomes is one of the approaches to achieve localized 
drug action, since their size and low penetrability through epithelium and connective 
tissue keeps the drug localized at the site of administration. 
 Localization of drug action results in enhancement of efficacy or potency of 
the drug and at the same time reduces its systemic toxic effects. The leishmaniasis 
causing organism in an intra-cellular parasite residing primarily in endocytotic 
vacuoles in phagocytic monomolecular cells. This being the primary site of niosomes 
update in-vivo. Antimonial encapsulated within niosomes are taken up by 
mononuclear cells resulting in localization of the drug causing an increase in potency 
and hence decrease in dose and toxicity. 
 The evolution of niosomal drug delivery is still at an infancy stage, but this 
type of drug delivery system has shown promise in cancer chemotherapy and anti-
leishmanial therapy. Niosomes may prove to be a convenient drug delivery system for 
other diseases. Niosomes are promising vehicle for drug delivery. It is less toxic and 
improves the therapeutic index of drugs by restricting its action to target cells. 
ADVANTAGES OF NIOSOMES 
1. Biocompatibility, the components of niosomes is formed in the body itself. 
2. Polar and nonpolar bioactive materials of various molecular sizes can be 
incorporated in the noisome. 
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3. The entrapped compounds are protected from degradation because of the 
limited permeability of niosomes. 
4. Targeting the drugs to liver, lungs and spleen are easier, macrophages of 
reticulo endothelial system take up niosomes immediately after systemic 
administration and direct them to liver and spleen. 
5. Niosomes exhibit flexibility in their structural characteristics. So that it can be 
suited for the desired situations. 
6. Niosomes can be administered by different routes (IV, intra peritoneal, oral 
and topical) and it can be used for a wide range of ailments. 
7. Niosomes can enhance the skin penetration of drugs. 
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LITERATURE AND REVIEW 
1. Mahmoud Mokhtar et al.,(2008) developed proniosomal gels or solutions of 
flurbiprofenbased on span 20 (Sp 20), span 40 (Sp 40),span 60 (Sp 60), and span 80 
(Sp 80) without and with cholesterol.Nonionic surfactant vesicles (niosomes)formed 
immediately upon hydrating proniosomal formulae. The entrapment efficiency (EE%) 
of flurbiprofen(a poorly soluble drug) was either determined by exhaustive dialysis of 
freshly prepared niosomesor centrifugation of freeze-thawed vesicles. The influence 
of different processing and formulation variables such as surfactant chain length, 
cholesterol content, drug concentration, total lipid concentration, negatively or 
positively charging lipids, and the pH of the dispersion medium on flurbiprofen EE% 
was demonstrated. Also, the release of the prepared niosomes in phosphate buffer (pH 
7.4) was illustrated. Results indicated that the EE% followed the trend Sp 60 
(C18)>Sp 40 (C16)>Sp 20 (C12)>Sp 80 (C18). Cholesterol increased or decreased the 
EE% depending on either the type of the surfactant or its concentration within the 
formulae. The maximum loading efficiency was 94.61% when the hydrating medium 
was adjusted to pH 5.5. Increasing total lipid or drug concentration also increased the 
EE% of flurbiprofen into niosomes. However, incorporation of either dicetyl 
phosphate (DCP) which induces negative charge or stearyl amine (SA) which induces 
positive charge decreased the EE% of flurbiprofen into niosomal vesicles. Finally, in 
vitro release data for niosomes of Sp 40 and Sp 60 showed that the release profiles of 
flurbiprofen from niosomes of different cholesterol contents is an apparently biphasic 
release process. As a result, this study suggested the potential of proniosomes as 
stable precursors for the immediate preparation of niosomal carrier systems. 
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2. Kumar, Dhiraj et al (2011) described a simple, accurate, precise and cost 
effective UV-VIS Spectrophotometric method for the estimation of Bosentan 
Monohydrate, an anti-hypertensive drug, in bulk and pharmaceutical dosage form. 
The solvent used was Acetonitrile and water in ratio of 10:90 and the lmax or the 
absorption maxima of the drug was found to be 272nm. A linear response was 
observed in the range of 10- 100µg/ml with a regression coefficient of 0.999. The 
method was then validated for different parameters as per the ICH (International 
Conference for Harmonization) guidelines. This method can be used for the 
determination of Bosentan Monohydrate in quality control of formulation without 
interference of the excipients. 
3. Gabriel J. Robbie et al., (2001) formulated 62.5 mg and 125 mg tablets for 
the long-term treatment of pulmonary arterial hypertension. In theoriginal NDA 
submission the sponsor proposed to use 1% sodium lauryl sulfate in water as the 
dissolution specification medium. However, the Office of Clinical Pharmacology 
and Biopharmaceutics suggested the use ofi `% sodium lauryl sulfate in water 
because of good ( /0 dissolved in 30 minutes) dissolution. After a series of 
teleconference calls, the Sponsor was requested to provide data supporting the 
lack of "sink conditions" with '% sodium lauryl sulfate in water. The sponsor has 
therefore performed comparative dissolution of bosentan tablets in( '% and 1% 
sodium lauryl sulfate in water and submitted the results in the present submission 
4. A.Ashok Kumar et al., (2011) described a simple, accurate, precise, specific 
and highly sensitivemethod for the determination of bosentan present in 
pharmaceutical dosage forms. Themethod is validated for the determination of 
Bosentan in bulk and tablet dosage form.Bosentanis a dual endothelin receptor 
antagonist used in the treatment of pulmonary arteryhypertension (PAH). The solvent 
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used was methanol: water (60:40) and the λmax or theabsorption maxima of the drug 
was found to be 270nm. A linear response was observed inthe range of 10-90µg/ml 
with a regression coefficient of 0.9993. The method was thenvalidated for different 
parameters as per the ICH (International Conference forHarmonization) guidelines. 
This method can be used for the determination of Bosentan inquality control of 
formulation without interference of the excipients. 
5. Ali Nasir et al., (2012) designed and developed novel drug delivery system 
(NDDS) having two prerequisites. First, itshould deliver the drug in accordance with a 
predetermined rate and second it should releasetherapeutically effective amount of 
drug at the site of action. Conventional dosage forms areunable to meet these 
requisites. Niosomes are essentially non-ionic surfactant-basedmultilamellar or 
unilamellar vesicles in which an aqueous solution of solute is entirely enclosedby a 
membrane resulting from the organisation of surfactant macromolecules as 
bilayer.Niosomes are formed on hydration of non-ionic surfactant film which 
eventually hydratesimbibing or encapsulating the hydrating aqueous solution. The 
proposed review deals withcomposition, methods of preparation, and applications of 
niosomes in the pharmaceutical field.The main aim of development of niosomes is to 
control the release of drug in a sustained way, Modification of distribution profile of 
drug and for targeting the drug to the specific body site. 
6. Dhiraj Kumar et al., (2011) described a simple, accurate, precise and cost 
effective UV-VIS Spectrophotometric method for the estimation of Bosentan 
Monohydrate, an anti-hypertensive drug, in bulk and pharmaceutical dosage form. 
The solvent used was Acetonitrile and water in ratio of 10:90 and the lmax or the 
absorption maxima of the drug was found to be 272nm. A linear response was 
observed in the range of 10- 100µg/ml with a regression coefficient of 0.999. The 
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method was then validated for different parameters as per the ICH (International 
Conference for Harmonization) guidelines. This method can be used for the 
determination of Bosentan Monohydrate in quality control of formulation without 
interference of the excipients. 
7. D.Akhilesh et al., (2012) approaches to stabilize niosomal drug delivery 
system without affecting its properties of merits have resulted in the development of 
the promising drug carrier “Proniosomes”. Proniosomes is a dry formulation using 
suitable carrier coated with non-ionic surfactants and can be converted into niosomes 
immediately before use by hydration. These proniosomederived niosomes are as good 
as or even better than conventional niosomes.Glipizide loaded Sorbitol, Maltodextrin 
and Mannitol based proniosomes were prepared by slurry method with different 
surfactant to cholesterol ratio.Theproniosome formulations were evaluated for FT-IR 
study, angle of repose and scanning electron microscopy.The niosomal suspensions 
were further evaluated for entrapment efficiency, In-vitro release study, Kinetic data 
analysis,Stability study. The result from SEM analyses has confirmed the coating of 
surfactant on the surface of carrier. The formulation based maltodextrin showed 
higher entrapment efficiency of 82.64 ± 1.25 and in-vitro release of 98% at the end of 
24hr was found to be best among the various formulations.The proniosome 
formulations were evaluated for FT-IR study, angle of repose and scanning electron 
microscopy and the result showed that the maltodextrin based formulation was best 
suited. Release was best explained by the zero order kinetics. Kinetic analysis shows 
that the drug release follows super case II transport diffusion.Maltodextrin based 
Proniosome formulation has showed appropriate stability for 90 days when compared 
with other carriers reconstituted niosomes by storing the formulation at refrigerator 
condition. 
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8. Madhav NVS et al., (2011) studied that Niosomes are formations of vesicles 
by hydrating mixture of cholesterol and nonionic surfactants. Different novel 
approaches used for delivering these drugs include liposomes, microspheres, 
nanotechnology, micro emulsions, antibody-loaded drug delivery, magnetic 
microcapsules, implantable pumps and niosomes. Niosomes and liposomes are 
equiactive in drug delivery potential and both increase drug efficacy as compared with 
that of free drug. Niosomes are preferred over liposomes because the former exhibit 
high chemical stability and economy. The application of vesicular (lipid vesicles and 
non-ionic surfactant vesicles) systems in cosmetics and for therapeutic purpose may 
offer several advantages. They improve the therapeutic performance of the drug 
molecules by delayed clearance from the circulation, protecting the drug from 
biological environment and restricting effects to target cells. This article focuses on 
the recent advances in niosomal drug delivery, potential advantages over other 
delivery systems, formulation methods, methods of characterization and the current 
research in the field of niosomes. Niosome appears to be a well preferred drug 
delivery system over liposome as niosome being stable and economic. Also niosomes 
have great drug delivery potential for targeted delivery of anti-cancer, antiinfective 
agents. Drug delivery potential of niosome can enhance by using novel concepts like 
proniosomes, discomes and aspasome. Niosomes also serve better aid in diagnostic 
imaging and as a vaccine adjuvant. Thus these areas need further exploration and 
research so as to bring out commercially available niosomal preparation. 
9. Rajesh z. mujoriya et al., (2011) studied that niosomes represent a promising 
drug delivery module. They present a structure similar to liposome and hence they can 
represent alternative vesicular systems with respect to liposomes, due to the niosome 
ability to encapsulate different type of drugs within their multi environmental 
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structure. Niosomes are thoughts to be better candidate’s drug delivery as compared 
to liposomes due to various factors like cost, stability etc. Various type of drug 
deliveries can be possible using niosomes like targeting, ophthalmic, topical, 
parentral, etc. 
10. RekhaRao et al ., (2010) developed that a number of novel drug delivery 
systems have emerged encompassing various routes of administration to achieve 
controlled and targeted drug delivery. Encapsulation of the drug in vesicular 
structures is one such system, which can be predicted to prolong the existence of the 
drug in systemic circulation and reduce the toxicity, if selective uptake can be 
achieved. Consequently, a number of vesicular drug delivery systems such as 
liposomes, niosomes, transferosomes, ethosomes and proniosomes were developed. 
Proniosomes are water soluble carrier particles that are coated with surfactant and can 
be hydrated to form niosomal dispersion immediately before use on brief agitation in 
hot aqueous media. This review presents an overview about proniosomes reporting 
the preparation methods, characterization techniques and the studies of penetration 
and transport of various drugs through skin. 
11. Astha Mishra et al., (2011) developed a drug delivery system which aims for 
delivering the therapeutic agent to the desired site of action.Pro-niosomes are 
promising drug carriers and are more advantageous than the conventional niosomes 
and liposomes. The advancements in the niosome lead to the evolution of 
proniosomal delivery systems. Proniosomes are non-ionicbased surfactant vesicles 
which may be hydrated immediately before use to yield aqueous niosome 
dispersions.They can incorporate both lipophilic as well as hydrophilic drugs. 
Proniosomal gel is basically used for the topical/transdermal applications.The  
givenarticle highlights all the salient features of a pro-niosomal gel, its advantages 
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over niosomes and liposomes, its method of preparation and its methods of 
characterization. 
12.  N.K. Jain et al.,(1998) developed a proniosome based transdermal drug 
delivery system of levonorgestrel (LN) was and extensively characterized both in 
vitro and in vivo. The proniosomal structure was liquid crystalline-compact niosomes 
hybrid which could be converted into niosomes upon hydration. The system was 
evaluated in vitro for drug loading, rate of hydration (spontaneity), vesicle size, 
polydispersity, entrapment efficiency and drug diffusion across rat skin. The effect of 
composition of formulation, amount of drug, type of Spans, alcohols and sonication 
time on transdermal permeation profile was observed. The stability studies were 
performed at 48C and at room temperature. The biological assay for progestational 
activity included endometrial assay and inhibition with the formation of corpora lutea. 
The study demonstrated the utility ofproniosomal transdermal patch bearing 
levonorgestrel for effective contraception. Ó 1998 Published by Elsevier Science. 
13. Gannu P. Kumar et al., (2011)  studied that vesicular systems are a novel 
means of drug delivery that can enhance bioavailability of encapsulated drug and 
provide therapeutic activity in a controlled manner for a prolonged period of time. 
Liposomes were the first such system but they suffer from a number of drawbacks 
including high cost and lack of stability at various pH. Niosomes are a nonionic 
surfactant vesicular system, which can be easily and reliably made in the laboratory. 
Many factors affect noisome formation such as the method of manufacture, nature of 
surfactant and encapsulated drug, temperature at which the lipids are hydrated and the 
critical packing parameter. This review describes all aspects of niosomes including 
their different compositions, the various methods of preparation, the effect of 
changing manufacturing parameters, methods of characterization, factors that affect 
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their stability, their use by various routes of administration, their therapeutic 
applications and the most important patents. The review also provides detailed 
information of the various types of niosomes that provide effective drug delivery. 
14. D. Akhilesh et al ., (2011) studied that niosomes are non-ionic surfactant 
vesicles obtained on hydration of synthetic nonionic surfactants, with or without 
incorporation of cholesterol or other lipids. They are vesicular systems similar to 
liposomes that can be used as carriers of amphiphilic and lipophilic drugs. Niosomes 
are promising vehicle for drug delivery and being non-ionic, it is less toxic and 
improves the therapeutic index of drug by restricting its action to target cells. This 
systemic review article deals with preparation methods, characterizations, factors 
affecting release kinetic, advantages, and applications of niosomes. They are lamellar 
structures that are microscopic in size. They are now widely used as alternative to 
liposomes. Niosomal dispersion in an aqueous phase can be emulsified in anon-
aqueous phase to regulate the delivery rate of drug and administer normal vesicle in 
external nonaqueous phase. Stable niosome dispersion must exhibit a constant particle 
size and a constant level of entrapped drug. Span 60 is the better surfactant of all 
because it is having high phase transition temperature and low HLB (Hydrophilic 
Lipophilic Balance) so it will form vesicles of good size.one more reason for the 
selection of span 60 and that was the critical packing factor which is between 0.5 and 
1 for this surfactant so it forms spherical vesicles. If CPP factor is below 0.5 it cause 
micelles to form and if it was above 1 it will form inverted vesicles. 
15. Madhav NVS et al (2011) developed thatniosomes are formations of vesicles 
by hydrating mixture of cholesterol and nonionic surfactants. Different novel 
approaches used for delivering these drugs include liposomes, microspheres, 
nanotechnology, micro emulsions, antibody-loaded drug delivery, magnetic 
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microcapsules, implantable pumps and niosomes. Niosomes and liposomes are 
equiactive in drug delivery potential and both increase drug efficacy as compared with 
that of free drug. Niosomes are preferred over liposomes because the former exhibit 
high chemical stability and economy. The application of vesicular (lipid vesicles and 
non-ionic surfactant vesicles) systems in cosmetics and for therapeutic purpose may 
offer several advantages. They improve the therapeutic performance of the drug 
molecules by delayed clearance from the circulation, protecting the drug from 
biological environment and restricting effects to target cells. This article focuses on 
the recent advances in niosomal drug delivery, potential advantages over other 
delivery systems, formulation methods, methods of characterization and the current 
research in the field of niosomes. Niosome appears to be a well preferred drug 
delivery system over liposome as niosome being stable and economic. Also niosomes 
have great drug delivery potential for targeted delivery of anti-cancer, antiinfective 
agents. Drug delivery potential of niosome can enhance by using novel concepts like 
proniosomes, discomes and aspasome. Niosomes also serve better aid in diagnostic 
imaging and as a vaccine adjuvant. Thus these areas need further exploration and 
research so as to bring out commercially available niosomal preparation. 
16. Alhatbabita et al., (2013) reviewed that an ideal drug delivery system delivers 
drug at rate dictated by the need of the body over the period of treatment and it 
channels the active entity solely to the site of action. Drug targeting can be defined as 
the ability to direct a therapeutic agent specifically to desired site of action with little 
or no interaction with nontarget tissue. Different novel approaches used for delivering 
these drugs include liposomes, microspheres, nanotechnology, micro emulsions, 
antibody loaded drug delivery, magnetic microcapsules, implantable pumps and 
niosomes. Niosomes are vesicles composed of non-ionic surfactants, which are 
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biodegradable, relatively nontoxic, more stable and inexpensive, an alternative to 
liposomes. They present a structure similar to liposome and hence they can represent 
alternative vesicular systems with respect to liposomes, due to the niosome ability to 
encapsulate different type of drugs within their multi environmental structure. 
Niosomes are thoughts to be better candidate’s drug delivery as compared to 
liposomes due to various factors like cost, stability etc.  
17. ShwetaPatidar et al.,(2012) formulated and evaluated Niosomes, a synthetic 
microscopic vesicles consisting of an aqueous concentration is enclosed in a bilayer 
consisting of cholesterol and nonionic surfactants to improve the low corneal 
permeability for effective management trigeminal neuralgia. Proniosomal gels of 
flupirtine Maleate were developed with span 20, span 60, span 80, tween 20 and 
tween 80 with cholesterol. Nonionic surfactant vesicles formed immediately upon 
hydrating proniosomal gel. The morphological characteristics, entrapment efficiency, 
In-vitro drug release, drug release kinetic, ocular irritation test, In vivo studies for 
Trigeminal neuralgia was determined. The entrapment efficiency (EE %) of flupirtine 
maleate was determined by centrifugation of freeze thawed vesicles followed the 
order span80 >span 60> span 20> tween 20> tween 80. The In vitro drug release 
studies showed that there was a prolong release of drug which followed Higuchi 
model. Niosome formed from span 80 and cholesterol is promising approach to 
prolong antinociception activity and improve permeation rate as compared to pure 
drug. 
18. Singh Neelam et al., (2010) formulated ceftriaxone sodium which is a third 
generation cephalosporin. This antibiotic cannot be absorbed orally owing to its very 
less permeation through GI epithelia. Other problem associated with the drug is its 
acid labile nature. The present study attempts to increase the intestinal permeability of 
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BCS Class III drug ceftriaxone sodium by using certain intestinal absorption 
enhancers. The blend of permeation enhancer, drug, and other excipients were 
incorporated into Beads to formulate the final dosage form. To enhance the 
permeation, intestinal permeation enhancers were used in various molar ratios with 
the drug. The effect of absorption enhancers on the lipophilicity of ceftriaxone sodium 
was determined by means of the n-octanol/water system. The changes in partition 
coefficient by the octanol/water system were confirmed using an in vitro transport 
model with excised animal intestinal membrane. The results indicated that there is 
significant improvement in the permeability of the drug and the extent of 
enhancement was highly dependent on the type of used absorption enhancer. 
Permeation enhancer and drug were formulated into beads further evaluated for 
permeability by using biological membrane. The release profile of ceftriaxone from 
beads was observed in both gastric and intestinal pH (7.4 buffer). Release of drug 
from the beads in both the media was found to occur predominantly by diffusion 
following non Fickian transport mechanism and was higher and more rapid in 
intestinal pH than in gastric pH. The results obtained from this study indicate that 
ceftriaxone sodium could be successfully delivered orally when formulated with 
permeation enhancers. 
19. YogeshGarg et al., (2010) developed a mucoadhesive multiparticulate 
sustained drug delivery system of pravastatin sodium, a highly water-soluble and 
poorly bioavailable drug, unstable at gastric pH Mucoadhesive microparticles were 
formulated using eudragit S100 and ethyl cellulose as mucoadhesive polymers. End-
step modification of w/o/o double emulsion solvent diffusion method was attempted 
to improve the purity of the product, that can affect the dose calculations of sustained 
release formulations and hence bioavailability. Microparticles formed were discrete, 
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free flowing, and exhibited good mucoadhesive properties. DSC and DRS showed 
stable character of drug in microparticles and absence of drug polymer interaction. 
The drug to polymer ratio and surfactant concentration had significant effect on mean 
particle size, drug release, and entrapment efficiency. Microparticles made with drug: 
eudragit S100 ratio of 1:3 (F6) exhibited maximum entrapment efficiency of 72.7% 
and ex vivo mucoadhesion time of 4.15 h. In vitro permeation studies on goat 
intestinal mucosa demonstrated a flux rate (1,243 µg/cm2/h) that was 169 times 
higher than the flux of pure drug. The gastric instability problem was overcome by 
formulating the optimized microparticles as enteric-coated capsules that provided a 
sustained delivery of the highly water-soluble drug for 12 h beyond the gastric region. 
The release mechanism was identified as fickian diffusion (n=0.4137) for the 
optimized formulation F6. Conclusively, a drug delivery system was successfully 
developed that showed delayed and sustained release up to 12 h and could be 
potentially useful to overcome poor bioavailability problems associated with 
pravastatin sodium. 
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AIM AND PLAN OF WORK 
Aim: 
 The aim of present study is to design and formulate proniosome based 
niosomal suspension of Bosentan monohydrate with increased bioavailability and 
sustained release. 
The important objectives of the proposed research work are:- 
• To carry out pre-formulation study of excipients and their compatibility with the 
API. 
• To increase the bioavailability of Bosentan monohydrate 
• Determination of λmax forBosentan monohydrate 
• To carry out preliminary investigation studies with different process variables to 
arrive at an optimum formulation revealing particle size suitable for oral delivery 
• Selection and optimization of the best formulation 
• To prepare niosomal formulation of Bosentan monohydrate with cholesterol and 
span 
• To perform stability studies on the most satisfactory formulation. 
• To reduce the dose related side effects which are caused by Bosentan 
monohydrate long term therapy 
• To reduce total dose amount of the drug in the formulation 
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PLAN OF WORK 
I. Preformulation studies 
1. Solubility analysis 
2. IR spectroscopy 
3. Melting point determination 
II. Compatibility studies by IR-Spectroscopy 
III. Standard calibration curve of Bosentan monohydrate 
IV. Percentage entrapment efficiency 
V. Vesicle size and morphology 
VI.       Characterization of proniosomal suspension. 
A. Ex-vivo drug permeation study 
B. Release kinetics 
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MATERIAL AND METHODS 
4.1List of equipment 
Sl.no Equipment Manufacturer 
1 Mechanical stirrer Remimotors 
2 magnetic stirrer Remi motors 
3 Hot air oven universal 
4 pH meter GeNej 
5 Deep freezer Science tech 
6 PC based double beam 
spectrophotometer-2202 
Systronic 
7 microscope Olympus India PVT LTD 
(Ch20iBRMP) Noida 
8 Centrifuse Remi 
9 Water bath Science tech 
10 Vortex Remi CM101 
11 Digital balance Axis 
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4.2List of chemicals 
Sl. No. Chemical name Manufacturer 
1 Bosentan monohydrate Parabolic Drugs Ltd., Chandigarh 
2 Methanol Worli Mumbai 
3 Ethanol Jiangsu huaxiinternationaltrade Co 
Ltd. CHINA 
4 Cholesterol Himedia, Mumbai 
5 Span 20 SD Fine, Mumbai 
6 Acetone Rankem, New Delhi 
7 N hexane Merke, Mumbai 
8 Pet ether Merke Mumbai 
9 Disodium hydrogen phosphate Merke Mumbai 
10 Dimethyl sulphoxide(DMSO) Merke Mumbai 
11 potassium dihydrogen phosphate Merke Mumbai 
12 Sodium chloride Merke Mumbai 
13 Chloroform Rankem, New Delhi 
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4.3 DRUG PROFILE 
Drug description 
Tracleer is the proprietary name for bosentan, an endothelin receptor antagonist that 
belongs to a class of highly substituted pyrimidine derivatives, with no chiral centers. 
It is designated chemically as 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-
phenoxy)[2,2´]-bipyrimidin-4-yl]- benzenesulfonamide monohydrate and has the 
following structural formula: 
Molecular weight- 569.64  
Molecular formula- C27H29N5O6S•H2O 
Description-Bosentan is a white to yellowish powder. 
Solubility- It is poorly soluble in water (1.0 mg/100 mL) and in aqueous solutions at 
low pH (0.1 mg/100 mL at pH 1.1 and 4.0; 0.2 mg/100 mL at pH 5.0). Solubility 
increases at higher pH values (43 mg/100 mL at pH 7.5). In the solid state, bosentan is 
very stable, is not hygroscopic and is not light sensitive. 
Dose- In adult patients 62.5 mg twice daily for 4 weeks and then increased to the 
maintenance dose of 125 mg twice daily for oral administration. 
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For pediatric patients aged 2 years or older- 2 mg/kg body weight twice daily(for oral 
administration) 
Excipients: corn starch, pre-gelatinized starch, sodium starch glycolate, povidone, 
glycerylbehenate, magnesium stearate, hydroxypropylmethylcellulose, triacetin, talc, 
titanium dioxide, iron oxide yellow, iron oxide red, and ethylcellulose. 
Melting point-195-198°C 
Standards- 99.0% to 102.0% 
Storage- Preserved in a well closed container. Keep in cool and dry place. 
Pharmacokinetic properties 
The pharmacokinetics of Bosentan has mainly been documented in healthy 
subjects. Limited data in patients show that the exposure to Bosentan in adult 
pulmonary arterial hypertension patients is approximately 2-fold greater than in 
healthy adult subjects. 
Bosentan displays dose and time-dependent pharmacokinetics. Clearance and 
volume of distribution decrease with increased intravenous doses and increase with 
time. After oral administration, the systemic exposure is proportional to dose up to 
500 mg. At higher oral doses, Cmax and AUC increase less than proportionally to the 
dose. 
Absorption 
In healthy subjects, the absolute bioavailability of bosentan is approximately 
50% and is not affected by food. The maximum plasma concentrations are attained 
within 3–5 hours. 
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Following a single 125 mg oral dose of bosentan in healthy volunteers, the 
Tmax, Cmax and half-life of bosentan were 4 h, 1500 ng/ml and 6 h, respectively. 
Reference: Tracleer (Bosentan) 125 mg FDA’s NDA submission: 49-073, Clinical 
Pharmacology and Biopharmaceutics Review. 
Distribution 
Bosentan is highly bound (> 98%) to plasma proteins, mainly albumin. 
Bosentan does not penetrate into erythrocytes. A volume of distribution of about 18 
litres was determined after an intravenous dose of 250 mg. 
Biotransformation and elimination 
After a single intravenous dose of 250 mg, the clearance was 8.2 L/h. The 
terminal elimination half-life (t1/2) is 5.4 hours. Upon multiple dosing, plasma 
concentrations of Bosentan decrease gradually to 50%–65% of those seen after single 
dose administration. This decrease is probably due to auto-induction of metabolizing 
liver enzymes. Steady-state conditions are reached within 3–5 days. Bosentan is 
eliminated by biliary excretion following metabolism in the liver by the cytochrome 
P450 isoenzymes, CYP2C9 and CYP3A4. Less than 3% of an administered oral dose 
is recovered in urine. Bosentan forms three metabolites and only one of these is 
pharmacologically active. This metabolite is mainly excreted unchanged via the bile. 
In adult patients, the exposure to the active metabolite is greater than in healthy 
subjects. In patients with evidence of the presence of cholestasis, the exposure to the 
active metabolite may be increased. Bosentan is an inducer of CYP2C9 and CYP3A4 
and possibly also of CYP2C19 and the P-glycoprotein. 
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In vitro, Bosentan inhibits the bile salt export pump in hepatocyte cultures.In 
vitro data demonstrated that Bosentan had no relevant inhibitory effect on the CYP 
isoenzymes tested (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1, 3A4). Consequently, 
Bosentan is not expected to increase the plasma concentrations of medicinal products 
metabolized by these isoenzymes 
Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both 
endothelin A and B (ETA and ETB) receptors. Bosentan decreases both pulmonary 
and systemic vascular resistance resulting in increased cardiac output without 
increasing heart rate. It is designated chemically as 4-tert-butyl-N-[6-(2-hydroxy-
ethoxy)-5-(2-methoxy-phenoxy)[2,2´]-bipyrimidin-4-yl]-benzenesulfonamide monohydrate 
and has the following structural formula. 
Mechanism of action 
Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both 
endothelin A and B (ETA and ETB) receptors. Bosentan decreases both pulmonary 
and systemic vascular resistance resulting in increased cardiac output without 
increasing heart rate. 
The neurohormone endothelin-1 (ET-1) is one of the most potent 
vasoconstrictors known and can also promote fibrosis, cell proliferation, cardiac 
hypertrophy and remodelling, and is pro-inflammatory. These effects are mediated by 
endothelin binding to ETA and ETB receptors located in the endothelium and 
vascular smooth muscle cells. ET-1 concentrations in tissues and plasma are increased 
in several cardiovascular disorders and connective tissue diseases, including 
pulmonary arterial hypertension, scleroderma, acute and chronic heart failure, 
myocardial ischaemia, systemic hypertension and atherosclerosis, suggesting 
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apathogenic role of ET-1 in these diseases. In pulmonary arterial hypertension and 
heart failure, in the absence of endothelin receptor antagonism, elevated ET-1 
concentrations are strongly correlated with the severity and prognosis of these 
diseases. 
Bosentan competes with the binding of ET-1 and other ET peptides to both 
ETA and ETB receptors, with a slightly higher affinity for ETA receptors (Ki = 4.1–
43 nanomolar) than for ETB receptors (Ki = 38-730 nanomolar). Bosentan 
specifically antagonises ET receptors and does not bind to other receptors. 
Side effects- There are some side effects of Bosentan monohydrate which must not be 
neglected while using this drug. 
• Nausea 
• stomach pain 
•  loss of appetite 
• Dark urine, clay-coloured stools or 
• Jaundice (yellowing of the skin or eyes). 
Less serious side effects may include 
• Headache and dizziness 
• flushing 
• swelling of the feet, ankles, or legs 
• upset stomach 
• fatigue 
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Precautions when taking Bosentan 
 Before taking Bosentan, tell your doctor or pharmacist if you are allergic to it, 
or if you have any other allergies. This product may contain inactive ingredients, 
which can cause allergic reactions or other problems. Talk to your pharmacist for 
more details. 
 Before using this medication, tell your doctor or pharmacist your medical 
history, especially of liver disease, anaemia.This drug may make you dizzy. Do not 
drive, use machinery, or do any activity that requires alertness until you are sure you 
can perform such activities safely. Avoid alcoholic beverages since they can increase 
the effects of dizziness and also increase the risk of serious liver problems. 
This medication must not be used during pregnancy. It may harm an unborn 
baby. If you become pregnant 
Indications 
Pulmonary Arterial Hypertension 
 Tracleer is indicated for the treatment of pulmonary arterial hypertension 
(PAH) (WHO Group 1) to improve exercise ability and to decrease clinical 
worsening. Studies establishing effectiveness included predominantly patients with 
NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable 
PAH (60%), PAH associated withconnective tissue diseases (21%), and PAH 
associated with congenital heart disease with left-to-right shunts (18%). 
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5.4 
Cholesterol 
Synonym:   
Molecular formula:  
Molecular weight:  
Structural formula: 
Description: 
Assay: 
Melting point:  
Solubility: 
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PROFILES FOR EXCIPIENTS 
Cholesterin, Cholesterolum. 
C22H46O 
386.67 
Cholesterol occurs as white or faintly yellow, almost 
odorless powder or granules which turns yellow 
colouron prolonged exposure to light and air.
95.0-97.0% 
150ºC. 
Soluble in acetone, chloroform, ethanol, methanol, 
hexane, and ether and practically insoluble in water.
 
 
 
to tan 
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Storage:  Stored in a well-closed container, proctected from light. 
Functional category:  Emollient and Emulsifying agent 
Applications: As an emulsifying agent, it imparts water-absorbing 
power to an ointment and also used as an emollient in 
varying concentrations. 
Safety: Cholesterol is essentially non-toxic and non-irritant 
material at the level employed asan excipient. 
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Synonym: 
Category: 
Molecular formula: 
Structural formula: 
Molecular weight: 
Density: 
Description: 
Functional category: 
Solubility: 
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Sorbitanmonosterate 
Span 20 
Non-ionic surface active agent. 
C18H34O6 
346.46 
1.032 g/mL at 25 °C(lit.) 
amber to sepia oil liquids, non-toxic, odorless. 
Solution, a small amount of dissolved in isopropyl 
alcohol and xylene.   
Emulsifying agent, non-ionic surfsctsnt, solubilizing 
agent, wetting agent and dispersing agent 
Soluble in most organic solvents. In water 
insoluble, they are dispersible 
 
 
 
 
although 
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Storage: it should be stored in a well closed container in a cool 
and dry place 
Safety: widely used in cosmetics, food products and topical 
pharmaceutical formulations and are regarded as 
nontoxic and nonirritant material 
Application: Used in pharmaceutical formulations as emulsifying 
agent in the preparation of creams, emulsion and 
ointment for topical application. 
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4.5. Materials and methods 
A. Materials 
Bosentan Monohydrate was a gift pack from “Parabolic Drugs LTD.” 
which is an ISO14001 – 2004 certified company(INDIA). 
Sorbitanmonosterate (span 20), and cholesterol (Chol; >99%) were purchased 
fromHimedia, Mumbai (INDIA).All other chemicals and solventswere of good 
quality, purchased from different certified Indian companies which is been 
mentioned earlier. 
B. Preparation of pro-niosomes 
 Pro-niosomes were prepared by the method reported by Voraet al. 
(1998) with some modifications. 
 In glass vials accuratelyweighed amounts of the surface-active agent 
were mixed with the appropriate amount of cholesterol to make 1 mmol 
total lipids.The amounts of cholesterol were added as 10% incrementsvaried 
from 0% to 60% of total lipids. 
 Bosentan monohydrate was added to thenonionic 
surfactant/cholesterol mixture. 
 Absolute ethanol (about400mg) was added to the mixtures then vials 
were tightly sealedand warmed in water bath (55–60~C) for5min while 
shaking untilcomplete dissolution of cholesterol. 
 To each of the formedparent solutions, about 0.16 ml hot distilled 
water (55–60~C) wasadded while warming in the water bath for 3–5 min 
till a clear ortranslucent solution was produced. 
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 The mixtures were allowed tocool down at room temperature and 
observed for the formation oftransparent solution, two phases liquid, and 
translucent, transparent or white creamy pro-niosomal gel.To obtaincharged 
pro-niosomes, SA or DCP were added to lipid mixtures thendissolved into 
ethanol as described above. SA or DSP did not affectthe final appearance of 
the developed proniosomes. 
 The obtainedformulations were kept in the same closed glass vials in 
dark for further characterization. 
C. Hydration step and formation of niosomes 
 Niosomes were prepared by hydration of the gels prepared 
asdescribed above. About 7 ml of phosphate buffer (pH7.4) was added into 
each vial followed by heating for 10 min at atemperature above 60~C in a 
water bath. Vortexing of the formulations was done two to three times 
during the 10 min heating. The final volume was adjusted to 10 ml by the 
same buffer. 
Formulations Cholesterol 
(mmol) 
Nonionic 
surfactant 
(mmol) 
Bosenan 
monohydrate(mg) 
Ethanol 
(mg) 
Water 
F3 0.2 0.8 20 400 0.16 
F4 0.3 0.7 20 400 0.16 
F5 0.4 0.6 20 400 0.16 
F6 0.5 0.5 20 400 0.16 
F7 0.6 0.4 20 400 0.16 
F8 0.7 0.3 20 400 0.16 
F9 0.8 0.2 20 400 0.16 
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Characterization of niosomal preparations 
A. Microscopic examination 
Small amounts of the formed niosomes were spread on a glassslide 
and examined for the vesicles structure and the presence ofinsoluble drug 
crystals using ordinary light microscope with varied magnification powers 
(10× and 40×). Also the size of niosomes was analyzed under Trinocular 
microscope usingocular micrometer and varnier caliper.Photomicrographs werealso 
taken for niosomes by TEM analysis to conform the structure and size of 
niosomes. 
B. Solubility determination of Bosentan monohydrate 
An excess amount of Bosentan monohydrate was added to each of 
distilledwater, and phosphate buffer (pH 5.5, 6.5, 6.8, 7.4, and 8). The mix-
tures were then kept at ambient temperature for 72 h in a shaker water bath 
to get equilibrium. The equilibrated samples were centrifuged at 3000 rpm 
for5min.  Aliquot portions of the supernatants were taken and properly 
diluted with phosphate buffer (pH 7.4) for quantification ofBosentan 
monohydratespectrophotometrically at 270 nm. 
C.  Determination of entrapment efficiency ofBosentan monohydrate in 
niosomes 
Dialysis method(Udupa et al., 1993). 
From the niosomal dispersion formed from pro-niosomes of Span 
20,unentrapped free drug was removed by placing 1 ml of the dispersion 
into a glass tube to which a cellophane membrane was attached to one side 
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and dialyzing exhaustively for 1 h each timeagainst 100 ml of phosphate 
buffer (pH 7.4). The dialysis of free Bosentan monohydrate was completed 
after about six changes of buffer solutionwhere no further Bosentan 
monohydrate could be detected in the solution. Thedrug content was 
determined spectrophotometrically at 270 nmagainst phosphate buffer (pH 
7.4) as a blank. Amount of entrappeddrug was obtained by subtracting 
amount of unentrapped drug from the total drug incorporated (Deepika 
and Indu, 2005). 
 

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×  
Freeze thawing/centrifugation method 
 1ml sample of prepared niosome was frozen for 24h at -20OC in 
Eppendorf tube. The frozen sample were removed fromthe freezer and let 
to thaw at room temperature, then centrifuged at 14,000 rpm for 40 min at 
4OC. Niosomal pellets were resuspended in phosphate buffer (pH 7.4) and 
then centrifuged again.This washing procedure was repeated two times to 
ensure thatthe unentrapped drug was no longer present in the void 
volumebetween the niosomes. The supernatant was separated each 
timefrom niosomal pellets and prepared for the assay of free drug.Each 
result was the mean of three determinations(±S.D.). The % entrapped 
Bosentan monohydrate was calculated as follows 
 

 =
 
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Assessment of Bosentan monohydrate release rates from niosomes 
The niosomal pellets prepared from proniosomes of Span 20were 
separated by centrifugation and washed twice as describedabove. The pellets 
were resuspended in 50 ml of phosphate buffer(pH 7.4). The suspension 
was placed in a 125 ml stoppered glassflask in a shaking water bath at 
37~C. 1 ml samples were with-drawn at the following intervals: 0, 1, 2, 3, 
4, 5, 6, 7, 8, 9, 10, 11 and 12hrafter incubation. Samples were centrifuged 
as mentioned beforeand supernatants were assayed at 270 nm. The 
percentage of drugrelease was plotted as a function of time(Sammour and 
Hassan, 1996). 
D. Ex-vivo permeation studies 
The rate of permeation of drugs from pro-niosomal formulations can be 
determined by using Franz diffusion cell.The drug release study of niosomes performed 
by Franz diffusion cell” consisted of a hollow glass cylindermade up of borosil glass. 
One end of the cylinder was covered with goat intestine. The diffusion cell consists of 
two compartments (donar and receptor) which were placed in a 250 ml borosil beaker. 
The content of diffusion cell was agitated with the help of a glass stirrer. 
Thereceptor cell contained a magnetic bead and was rotated at a constant speed. The 
temperature in a donar and receptor cells was maintained at 37±0.5ºC with the help of 
thermostat. Two milliliters of each formulation was subjected to release studies. 
Phosphate buffer (20 ml) pH 7.4 was placed in the receptor cell. Two milliliters 
sample of each formulation was transferred to the dissolution cell.  
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One milliliter sample was withdrawn from the receptor cell at specified time 
intervals. At each time immediately after the removal of the sample, the medium was 
compensated with fresh phosphate buffer (pH 7.4). The samples were analyzed for 
Bosentan Monohydrate content using a UV spectrophotometer (PC based double 
beam Systronic UV spectrophotometer 2202) at λ max 270 nm. 
E. Statistical analysis 
The data were reported as mean± S.D.(n = 3) and statistical analysis of 
the data was carried out using one way ANOVA followed by LSD test at a 
level of significant of P< 0.05. 
Chapter 5  Result and discussion 
Department of Pharmaceutics 77 JKKMMRF College of Pharmacy 
RESULTS AND DISCUSSION 
5.1. Preformulation studies: 
5.1.1. Solubility analysis: 
Table 5.1: Solubility of Bosentan monohydrate in various solvent 
Name of solvents Solubility 
Water Practically insoluble 
Pbs (6.8) Slightly soluble 
Pbs (7.4) Practically insoluble 
DMSO Soluble 
Ethanol Soluble 
Methanol Slightly soluble 
n-hexane Practically insoluble 
Acetone Soluble 
Pet ether Practly insoluble 
Chloroform Soluble 
Acetonitrile Soluble 
dichloromethane Soluble 
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5.1.2a. determination of λ max: 
Fig.no:5.1: λ maxof Bosentan monohydrate 
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5.1.2b. IR spectroscopy: 
Fig.no:5.2 FT-IR Spectra of Bosentan monohydrate 
 
Fig.no:5.3 FT-IR Spectra of Bosentan monohydrate+ Cholesterol 
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Table 5.2: FTIR Spectral analysis of pure drug 
Sl no Functional groups Observed frequencies 
1. OH  Stretching 3433-3000 
2. C-H stretching of CH2 2959 
3. C=C stretching 1566 
4. O-H deformations 
vibrations 
1495 
5. CH2 in plane deformations 1451 
6. CH3  deformation 1391 
7. CH3 deformation 1342 
8. C-O stretching of carbonyl 1247 
9. C-O-C stretching 1169 
10. CH2 out of bending 
vibration 
1017 
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Table 5.3: FTIR Spectral analysis of Drug + cholesterol 
Sl no Functional groups Observed frequencies 
1. OH  Stretching 3434 
2. C-H stretching of CH2 2940 
3. C=C stretching 1565 
4. O-H deformations 
vibrations 
1457 
5. CH3  deformation 1383 
6. CH3 deformation 1344 
7. C-O stretching of 
carbonyl 
1247 
8. C-O-C stretching 1170 
9. CH2 out of bending 
vibration 
1061 
 
5.1.3. Melting point determination 
 The melting point of Bosentan monohydrate was found to be 196oC which was 
found to be within the reported range of 195-198oC. It complies with the standards 
thus indicate that, the sample was pure. 
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5.3. Standard calibration curve of Bosentan monohydrate 
Table no:5.4Standard calibration curve of Bosentan monohydrate 
S.no Concentration 
(µg/ml) 
Absorbance(nm) 
(In ethanol) 
Absorbance(nm) 
(in pH 7.4 
PBS+sls) 
1 0 0.000 0.000 
2 5 0.303 0.039 
3 10 0.388 0.112 
4 15 0.509 0.200 
5 20 0.602 0.258 
6 25 0.698 0.325 
7 30 0.744 0.395 
8 35 0.841 0.449 
9 40 0.977 0.512 
10 45 1.041 0.582 
11 50 1.170 0.619 
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Fig.no:5.4Standard calibration curve of Bosentan monohydrate in ethanol  
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Fig.no:5.5 Standard calibration curve of Bosentan monohydrate in phosphate 
buffer +sodium lauryl sulphate 
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5.4 Percentage entrapment efficiency
 Table no:5.5 Percentage entrapment eff
Fig no:5.6 Percentage drug entrapment efficiency of Bosentan monohydrate
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iciency of Bosentan monohydrate
  
F5
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F9
FORMULATIONS
%ENTRAPMENT
 %ENTRAPMENT EFFICIENCY
80.225 
85.198 
78.796 
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76.331 
72.817 
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5. Vesicle size and morphology 
Fig no:5.7Microphoto graph of groups of noisome at 10X Magnification 
 
Fig no:5.8Microphoto graph of groups of noisome at 10X Magnification 
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Fig no:5.9Microphotograph of groups of noisome at 45X Magnification 
 
Fig no:5.10Microphoto graph of groups of noisome at 45X Magnification 
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Fig no:5.11Transmission  Electron Microscopic Image1 
 
Fig no:5.12Transmission  Electron Microscopic Image2 
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Table no:5.6
SIZE 
RANGE(µm) F3 
0.6-0.8 8 
0.8-1 14 
1-1.2 42 
1.2-1.4 21 
1.4-1.6 15 
Fig no:5.13 Graphical representation of Particle size distribution of Bosentan 
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 Particle size data of Bosentan monohydrate
F4 F5 F6 F7 F8
14 11 11 5 3
26 17 12 16 15
38 41 51 48 51
14 18 18 19 24
8 13 8 12 7
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VI. Characterization of proniosomal suspension 
A. In-vitro drug permeation study 
Table no: 5.7% Cumulative drug release of Bosentan monohydrate in all 
formulations 
TIME(Hr) F3 F4 F5 F6 F7 F8 F9 
1 17.500 29.167 23.500 24.667 17.667 12.917 12.667 
2 17.583 30.167 24.167 25.833 20.917 14.667 16.583 
3 28.333 38.250 26.333 30.667 25.750 18.000 18.000 
4 36.333 41.500 30.167 33.083 31.000 22.500 21.083 
5 39.000 42.167 33.333 37.167 33.917 25.167 25.000 
6 40.917 45.750 37.333 41.000 37.500 26.750 27.667 
7 54.417 63.833 46.833 47.250 41.500 32.500 29.250 
8 55.333 65.417 51.333 50.250 44.667 35.583 31.417 
9 56.833 65.833 54.000 53.833 47.000 38.000 33.667 
10 58.083 66.833 58.000 57.000 48.833 39.500 36.333 
11 58.583 68.083 61.917 59.250 50.667 41.917 37.833 
12 59.750 70.000 63.250 59.667 51.000 43.167 38.417 
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Fig no:5.14 % Cumulative drug release curve of  all formulations 
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B. Release kinetics 
Table no:5.8 Release kinetic parameters of formulation F3 
 
 
 
Time 
(hr) Absorbance 
Conc. 
(µg/ml) % CDR 
% 
DRM 
SQRT 
Time 
(hr) 
log % 
CDR 
Log 
time 
log % 
DRM 
1 0.237 20.17 40.333 59.667 1.000 1.606 0.000 1.776 
2 0.239 20.33 40.667 59.333 1.414 1.609 0.301 1.773 
3 0.24 20.42 40.833 59.167 1.732 1.611 0.477 1.772 
4 0.251 21.33 42.667 57.333 2.000 1.630 0.602 1.758 
5 0.267 22.67 45.333 54.667 2.236 1.656 0.699 1.738 
6 0.271 23.00 46.000 54.000 2.449 1.663 0.778 1.732 
7 0.284 24.08 48.167 51.833 2.646 1.683 0.845 1.715 
8 0.289 24.50 49.000 51.000 2.828 1.690 0.903 1.708 
9 0.299 25.33 50.667 49.333 3.000 1.705 0.954 1.693 
10 0.303 25.67 51.333 48.667 3.162 1.710 1.000 1.687 
11 0.305 25.83 51.667 48.333 3.317 1.713 1.041 1.684 
12 0.309 26.17 52.333 47.667 3.464 1.719 1.079 1.678 
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Table no:5.9 Release kinetic parameters of formulation F4 
 
 
 
 
Time 
(hr) Absorbance 
Conc. 
(µg/ml) % CDR 
% 
DRM 
SQRT 
Time 
(hr) 
log % 
CDR 
Log 
time 
log % 
DRM 
1 0.241 20.50 41.000 59.000 1.000 1.613 0.000 1.771 
2 0.24 20.42 40.833 59.167 1.414 1.611 0.301 1.772 
3 0.25 21.25 42.500 57.500 1.732 1.628 0.477 1.760 
4 0.261 22.17 44.333 55.667 2.000 1.647 0.602 1.746 
5 0.273 23.17 46.333 53.667 2.236 1.666 0.699 1.730 
6 0.282 23.92 47.833 52.167 2.449 1.680 0.778 1.717 
7 0.289 24.50 49.000 51.000 2.646 1.690 0.845 1.708 
8 0.296 25.08 50.167 49.833 2.828 1.700 0.903 1.698 
9 0.304 25.75 51.500 48.500 3.000 1.712 0.954 1.686 
10 0.307 26.00 52.000 48.000 3.162 1.716 1.000 1.681 
11 0.31 26.25 52.500 47.500 3.317 1.720 1.041 1.677 
12 0.312 26.42 52.833 47.167 3.464 1.723 1.079 1.674 
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Table no:5.10 Release kinetic parameters of formulation F5 
 
 
 
Time 
(hr) Absorbance 
Conc. 
(µg/ml) % CDR 
% 
DRM 
SQRT 
Time 
(hr) 
log % 
CDR 
Log 
time 
log % 
DRM 
1 0.235 20.00 40.000 60.000 1.000 1.602 0.000 1.778 
2 0.213 18.17 36.333 63.667 1.414 1.560 0.301 1.804 
3 0.223 19.00 38.000 62.000 1.732 1.580 0.477 1.792 
4 0.237 20.17 40.333 59.667 2.000 1.606 0.602 1.776 
5 0.248 21.08 42.167 57.833 2.236 1.625 0.699 1.762 
6 0.301 25.50 51.000 49.000 2.449 1.708 0.778 1.690 
7 0.315 26.67 53.333 46.667 2.646 1.727 0.845 1.669 
8 0.321 27.17 54.333 45.667 2.828 1.735 0.903 1.660 
9 0.325 27.50 55.000 45.000 3.000 1.740 0.954 1.653 
10 0.331 28.00 56.000 44.000 3.162 1.748 1.000 1.643 
11 0.334 28.25 56.500 43.500 3.317 1.752 1.041 1.638 
12 0.335 28.33 56.667 43.333 3.464 1.753 1.079 1.637 
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Table no:5.11 Release kinetic parameters of formulation F6 
 
 
Time 
(hr) Absorbance 
Conc. 
(µg/ml) % CDR 
% 
DRM 
SQRT 
Time 
(hr) 
log % 
CDR 
Log 
time 
log % 
DRM 
1 0.217 18.50 37.000 63.000 1.000 1.568 0.000 1.799 
2 0.211 18.00 36.000 64.000 1.414 1.556 0.301 1.806 
3 0.239 20.33 40.667 59.333 1.732 1.609 0.477 1.773 
4 0.253 21.50 43.000 57.000 2.000 1.633 0.602 1.756 
5 0.277 23.50 47.000 53.000 2.236 1.672 0.699 1.724 
6 0.288 24.42 48.833 51.167 2.449 1.689 0.778 1.709 
7 0.289 24.50 49.000 51.000 2.646 1.690 0.845 1.708 
8 0.301 25.50 51.000 49.000 2.828 1.708 0.903 1.690 
9 0.306 25.92 51.833 48.167 3.000 1.715 0.954 1.683 
10 0.311 26.33 52.667 47.333 3.162 1.722 1.000 1.675 
11 0.319 27.00 54.000 46.000 3.317 1.732 1.041 1.663 
12 0.329 27.83 55.667 44.333 3.464 1.746 1.079 1.647 
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Table no:5.12 Release kinetic parameters of formulation F7 
 
 
  
Time 
(hr) Absorbance 
Conc. 
(µg/ml) % CDR 
% 
DRM 
SQRT 
Time 
(hr) 
log % 
CDR 
Log 
time 
log % 
DRM 
1 0.203 17.33 34.667 65.333 1.000 1.540 0.000 1.815 
2 0.205 17.50 35.000 65.000 1.414 1.544 0.301 1.813 
3 0.217 18.50 37.000 63.000 1.732 1.568 0.477 1.799 
4 0.241 20.50 41.000 59.000 2.000 1.613 0.602 1.771 
5 0.245 20.83 41.667 58.333 2.236 1.620 0.699 1.766 
6 0.263 22.33 44.667 55.333 2.449 1.650 0.778 1.743 
7 0.279 23.67 47.333 52.667 2.646 1.675 0.845 1.722 
8 0.283 24.00 48.000 52.000 2.828 1.681 0.903 1.716 
9 0.291 24.67 49.333 50.667 3.000 1.693 0.954 1.705 
10 0.307 26.00 52.000 48.000 3.162 1.716 1.000 1.681 
11 0.312 26.42 52.833 47.167 3.317 1.723 1.041 1.674 
12 0.315 26.67 53.333 46.667 3.464 1.727 1.079 1.669 
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Table no:5.13 Release kinetic parameters of formulation F8 
 
 
 
Time 
(hr) Absorbance 
Conc. 
(µg/ml) % CDR 
% 
DRM 
SQRT 
Time 
(hr) 
log % 
CDR 
Log 
time 
log % 
DRM 
1 0.203 17.33 34.667 65.333 1.000 1.540 0.000 1.815 
2 0.205 17.50 35.000 65.000 1.414 1.544 0.301 1.813 
3 0.217 18.50 37.000 63.000 1.732 1.568 0.477 1.799 
4 0.241 20.50 41.000 59.000 2.000 1.613 0.602 1.771 
5 0.245 20.83 41.667 58.333 2.236 1.620 0.699 1.766 
6 0.263 22.33 44.667 55.333 2.449 1.650 0.778 1.743 
7 0.279 23.67 47.333 52.667 2.646 1.675 0.845 1.722 
8 0.283 24.00 48.000 52.000 2.828 1.681 0.903 1.716 
9 0.291 24.67 49.333 50.667 3.000 1.693 0.954 1.705 
10 0.307 26.00 52.000 48.000 3.162 1.716 1.000 1.681 
11 0.312 26.42 52.833 47.167 3.317 1.723 1.041 1.674 
12 0.315 26.67 53.333 46.667 3.464 1.727 1.079 1.669 
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Table no:5.14 Release kinetic parameters of formulation F9 
 
 
 
Time 
(hr) Absorbance 
Conc. 
(µg/ml) % CDR 
% 
DRM 
SQRT 
Time 
(hr) 
log % 
CDR 
Log 
time 
log % 
DRM 
1 0.239 20.33 40.667 59.333 1.000 1.609 0.000 1.773 
2 0.24 20.42 40.833 59.167 1.414 1.611 0.301 1.772 
3 0.241 20.50 41.000 59.000 1.732 1.613 0.477 1.771 
4 0.269 22.83 45.667 54.333 2.000 1.660 0.602 1.735 
5 0.291 24.67 49.333 50.667 2.236 1.693 0.699 1.705 
6 0.303 25.67 51.333 48.667 2.449 1.710 0.778 1.687 
7 0.307 26.00 52.000 48.000 2.646 1.716 0.845 1.681 
8 0.309 26.17 52.333 47.667 2.828 1.719 0.903 1.678 
9 0.317 26.83 53.667 46.333 3.000 1.730 0.954 1.666 
10 0.319 27.00 54.000 46.000 3.162 1.732 1.000 1.663 
11 0.32 27.08 54.167 45.833 3.317 1.734 1.041 1.661 
12 0.324 27.42 54.833 45.167 3.464 1.739 1.079 1.655 
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Fig no:5.15First order release kinetics of Bosentan monohydrate of 
formulationF3 
 
 
Fig no:5.16Firstorder release kinetics of Bosentan monohydrate of 
formulationF4 
 
R² = 0.972
1.660
1.680
1.700
1.720
1.740
1.760
1.780
1.800
0 2 4 6 8 10 12 14
T
im
e
 (
h
r)
log % DRM
1 Order
R² = 0.971
1.640
1.660
1.680
1.700
1.720
1.740
1.760
1.780
0 2 4 6 8 10 12 14
1 ORDER
Chapter 5  Result and discussion 
Department of Pharmaceutics 100 JKKMMRF College of Pharmacy 
Fig no:5.17 First  order release kinetics of Bosentan monohydrate 
of formulation F5 
 
Fig no:5.18Higuchi release kinetics of Bosentan monohydrate of formulationF6 
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Fig no:5.19 First  order release kinetics of Bosentan monohydrate of 
formulationF7 
 
Fig no:5.20First  order release kinetics of Bosentan monohydrate of 
formulationF8 
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Fig no:5.21Higuchi release kinetics of Bosentan monohydrate of formulationF9 
 
Table no:5.15Value of coefficient of regression (R2) of all formulations 
Formulation 
R2 value 
Best fit model Zero Order 
Model 
First Order 
Model 
Higuchi 
Model 
Korsmeyer-
Peppas Model 
F3 0.9687 0.9729 0.9541 0.8835 First order 
F4 0.9648 0.9718 0.9716 0.9208 First order 
F5 0.8711 0.8837 0.8562 0.7672 First order 
F6 0.9397 0.9137 0.9656 0.9337 Higuchi model 
F7 0.9731 0.9791 0.9621 0.8985 First order 
F8 0.9777 0.9844 0.9748 0.9276 First order 
F9 0.8813 0.8966 0.9209 0.8945 Higuchi model 
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DISCUSSION 
 Niosome are used to provide better penetration trough gastrointestinal tract, 
and thus provides better bioavailability. It also provides sustained release for drugs. 
Bosentan is used for treatment pulmonary hypertension.  Bioavailability of Bosentan 
monohydrate was found to be increased in niosomal form as compare to other forms. 
 The Bosentan monohydrate identified by white crystalline powder, and bitter 
in taste, which is compliance with standard value of Bosentan monohydrate, its shows 
starting melting at 195ºC which was between the range, solubility of Bosentan 
monohydrate in different solvents was performed. The study indicate the affinity of 
Bosentan monohydrate towards non-aqueous solvents The solubility of Bosentan 
monohydrate was shown in several solvents and it was found to be soluble in some 
solvents like ethanol , methanol, acetone and dichloromethane and insoluble in some 
solvents as well like distilled water, n-hexane, pet ether etc.  
 The drug was identified by FT-IR spectra shown in (figure 8). FT-IR spectra 
of pure drug and drug with polymer were shown, no interaction was seen in both 
spectra. IR spectra of pure drug and its polymer used in formulations indicate that 
there were no structural changes caused by excipients. 
 The absorption maxima were determined by using UV/visible 
spectrophotometer found at 270nm which complies with standard value.In ethanol, 
absorbance was determined between ranges of 0.303 to 1.710. The determined 
absorbance shows linear absorption and value of the coefficient of regration was 
found to be R² = 0.972and equation of line was found to be y = 0.0207x + 0.1441. In 
phosphate buffer, absorbance was determined ranges “between” 0.039 to 
0.619.calibration curve of Bosentan monohydrate show straight –line with coefficient 
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of regration was found to be R2=0.9968 was found and equation of line was found to 
be y = 0.0129x - 0.0055 
 Out of different methods of preparation of noisome “formation of noisome 
from pro-niosome“was selected, cholesterol and span 20 were used in noisome 
formation. Different concentration of non-ionic surfactant was used for preparation of 
noisome 
 Temperature was maintained “between "55-60oC”. Below 40oc temperature 
the noisome was not formed and above temperature 80.c the formulation changes in 
color before formation of pro-niosomal suspension. 
 Totally eleven formulations were formulated numbered from F1 to F11, out of 
which noisome were not observed as per our expectations in four formulations namely 
F1,F2, F10 and F11. So the first two and last two formulations were excluded from 
further evaluations and only the formulation from F3 to F9 were performed and been 
mentioned in the formulation chart. 
 Particle size analysis was performed by ocular light microscope the size range 
of the niosome was found between the ranges of 0.6-1.6 µm. The main factor 
affecting the size of noisome is cholesterol and HLB of non-ionic surfactant. 
Formulation F4 was found to have lesser particle size. Transmission electron 
microscopies shown noisome are spherical in shape  
 The entrapment efficiency was performed to estimate the actual amount of 
drug being entrapped. Maximum percent drug entrapment was seen in formulation F4 
and minimum percent drug entrapment was seen in formulation F8.. 
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 Under perfect sink condition, the drug release rate depends on concentration of 
cholesterol and surfactant and drug release behavior of Bosentan monohydrate was 
studied in phosphate buffer (pH 7.4) at 37±2Oc the curve was obtained after plotting 
cumulative amount of drug released from each formulation against time. Formulation 
F4 (70.00%) showed maximum release while other formulation showed less amount 
of drug release in 12 hrs. Formulation F4 follows drug release by first order model. 
 To predict the release pattern of Bosentan monohydrate from noisome 
formulation batches (F3 to F9) correlation coefficient and rate constant was calculated 
for zero order, first order, Higuchi order and Korsmeyer-Peppas Model kinetics. The 
studies of drug release kinetics showed that majority of the formulations are governed 
by first order kinetic model. 
 F4 formulation show maximum permeation flux of Bosentan monohydrate and 
the permeation of drug were enhanced by surfactant present in niosomes. 
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SUMMARY AND CONCLUSION 
Summary 
 Niosomes or non-ionic surfactant vesicles are one of the many different 
carriers for transporting a drug molecule to its site of action. They are uni-lamellar or 
multi-lamellar vesicles where in an aqueous solution is enclosed in a highly ordered 
bilayer made up of non-ionic surfactants with or without cholesterol. They can entrap 
both hydrophilic and hydrophobic drugs. Niosomes are preferred over other vesicular 
system because of  chemical stability, low toxicity, non-ionic nature, better bio-
availability of drug at site, good intrinsic  skin permeation and they are weakly 
immunogenic. Niosomes protect drugs against acidic and enzymatic degradation. 
Niosomes showed excellent entrapment efficiency and in-vitro drug release can be 
manipulated by the type of surfactant and type of its charge. 
 Formulation of Bosentan monohydrate was performed by using cholesterol, 
span 20, and ethanol. Preformulation study like solubility, melting pointand 
absorption maxima was performed and further IR was also performed which shows no 
interaction between drug and excipients used in the formulation the formulation was 
performed by the technique ”noisome formulation from proniosome”. 
 The Niosomes was characterized by entrapment efficiency that shows good 
entrapment of drug up to 85.198%. 
 Then the particle size of niosomes was analyzed using, transmission electron 
microscopewhich shows that the size is within the expected range and later it was 
confirmed by TEM analysis. 
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 Ex-vivo drug permeation study was performed on freshly excised goat 
intestine and the study shows better bioavailability of Bosentan in the form of 
niosome. 
 Further the in-vitro release was performed and the release kinetics was 
foundand plotted for different modelsand found that maximum formulations follow 
the first order kinetics. 
Conclusion 
 The present study demonstrated the successful preparation of Bosentan 
monohydrate niosomeby “noisome prepared from proniosome method” and their 
evaluation. Formulation F4 shows better bioavailability as well as sustained release as 
compare to other formulations. Based on the evaluations and the results the Bosentan 
monohydrate noisome containing span 20 and cholesterol be taken as an ideal 
formulation. 
 
Table No-6 
CALIBRATION CURVE OF RAMIPRIL IN                                                  
PHOSPHATE BUFFERED SALINE pH 7.4.  
 
S.No. CONCENTRATION (µg/ml) ABSORBANCE ± SD* 
1 5 0.196 ± 0.0005  
2 10 0.390 ± 0.007 
3 15 0.587 ± 0.0057 
4 20 0.781 ± 0.0065 
5 25 0.974 ± 0.0045 
6 30 1.182 ± 0.0091 
7 35 1.382 ± 0.0043 
8 40 1.564 ± 0.015 
9 45 1.747 ± 0.016 
10 50 1.972 ± 0.0087  
 
          n = 3*                                                                                         γ =  0.999901195                                                          
 
 
 
 
 
 
 
  
 
Table No: 7 
ENTRAPMENT EFFICIENCIES OF RAMIPRIL NIOSOMES USING                           
SPAN 60: CHOLESTEROL (1:1) AT DIFFERENT MOLAR 
CONCENTRTIONS. 
 
 
S.NO 
 
 
MOLAR CONCENTRATION 
 
% ENTARPMRNT 
EFFICIENCY ± SD* 
 
 
1 
 
 
20 µmol 
 
32.28 ± 0.33 
 
2. 
 
 
30 µmol 
 
 
35.30 ± 0.17 
 
3. 
 
 
40 µmol 
 
34.11 ± 0.58 
 
4. 
 
 
50 µmol 
 
30.62 ±0.69 
 
5. 
 
 
60 µmol 
 
28.33 ± 0.47 
 
6. 
 
 
70 µmol 
 
25.94 ± 0.28 
 
n=3* 
 
 
 
 
 
 
 
 
 
  
 
Table No: 8 
FORMULATION OF RAMIPRIL NIOSOMES 
 
S.NO 
 
FORMULATION 
 
SURFACTANT 
RATIO OF 
SURFACTANT CHOLESTEROL 
 
1. 
 
F1 
 
SPAN 60 
 
1 
 
1 
 
2. 
 
F2 
 
SPAN 60 
 
2 
 
1 
 
3. 
 
F3 
 
SPAN 60 
 
3 
 
1 
 
4. 
 
F4 
 
SPAN 60 
 
4 
 
1 
 
5. 
 
F5 
 
SPAN 60 
 
5 
 
1 
 
6. 
 
F6 
 
SPAN 60 
 
6 
 
1 
 
7. 
 
F7 
 
SPAN 20 
 
1 
 
1 
 
8. 
 
F8 
 
SPAN 40 
 
1 
 
1 
 
9. 
 
F9 
 
SPAN 80 
 
1 
 
1 
 
10. 
 
F10 
 
TWEEN 60 
 
1 
 
1 
 
Drug concentration used in each formulation kept as constant 2.5mg/5ml. 
In ratio 1 stands for 30µmol.       
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   % ENTRAPMENT EFFICIENCY OF DIFFERENT FORMULATIONS 
 
S.NO 
 
 
FORMULATION 
 
SURFACTANT 
RATIO OF  
% ENTRAPMENT 
EFFICIENCY ± SD* SURFACTANT CHOLESTEROL 
 
1. 
 
F1 
 
SPAN 60 
 
1 
 
1 
 
35.05±0.46 
 
2. 
 
F2 
 
SPAN 60 
 
2 
 
1 
 
30.76±0.65 
 
3. 
 
F3 
 
SPAN 60 
 
3 
 
1 
 
29.16±0.56 
 
4. 
 
F4 
 
SPAN 60 
 
4 
 
1 
 
28.06±0.71 
 
5. 
 
F5 
 
SPAN 60 
 
5 
 
1 
 
27.57±0.39 
 
6. 
 
F6 
 
SPAN 60 
 
6 
 
1 
 
25.28±0.50 
 
7. 
 
F7 
 
SPAN 20 
 
1 
 
1 
 
29.42±0.57 
 
8. 
 
F8 
 
SPAN 40 
 
1 
 
1 
 
33.54±0.65 
 
9. 
 
F9 
 
SPAN 80 
 
1 
 
1 
 
26.05±0.70 
 
10. 
 
F10 
 
TWEEN 60 
 
1 
 
1 
 
22.05±0.58 
 
n=3* 
        Table No: 10 
   COMPARISON OF INVITRO RELEASE PROFILE OF RAMIPRIL NIOSOMES 
 
TIME IN HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* 
F1 (SPAN 60 1:1) F2 (SPAN 60 1:2) F3 (SPAN 60 1:3) F4 (SPAN 60 1:4) F5 (SPAN 60 1:5) 
0.00 0 ±0 0 ±0 0 ±0 0 ±0 0 ±0 
0.25 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
0.5 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
0.75 0 ± 0 3.7 ± 1.80 4.7 ± 0.81 4.8 ± 0.51 5.5 ± 0 .61 
1.0 4.1 ± 0.24 7.4 ± 1.09 8.2 ± 1.02 7.7 ± 0.99 8.6 ± 1.32 
1.5 7.7 ± 1.71 11.5 ± 0.87 12.3 ± 0.98 13.2 ± 0.69 13.3 ± 1.00 
2.0 11.3 ± 1.75 15.7 ± 0.96 16.1 ± 1.84 17.6 ± 1.59 18.4 ± 1.00 
2.5 15.9 ± 1.67 19.6 ± 1.46 21.4 ± 1.51 22.6 ± 2.09 25.5 ± 1.49 
3.0 19.7 ± 2.54 23.8 ± 1.07 24.3 ± 2.03 26.8 ± 1.88 30.9 ± 1.48 
3.5 24.5 ± 2.01 26.5 ± 2.48 29.8 ± 1.42 30.0 ± 2.00 34.9 ± 1.79 
4.0 26.7 ± 1.76 29.7 ± 0.75 32.1 ± 1.52 31.7 ± 1.45 39.3 ± 2.20 
4.5 29.3 ± 1.10 31.7 ± 1.59 35.5 ± 1.70 34.1 ± 0.70 42.6 ± 1.29 
5.0 31.4 ± 1.95 37.0 ±1.62 38.3 ± 1.65 36.1 ± 1.29 44.1 ± 0.89 
5.5 33.9 ± 0.60 39.7 ± 0.40 41.1 ± 0.96 40.7 ± 1.29 47.8 ± 1.29 
6.0 34.8 ± 0.40 42.6 ± 1.49 42.6 ± 0.47 45.6 ± 1.30 51.0 ±2.09 
6.5 37.2 ± 1.04 46.6 ± 1.85 46.0 ± 1.18 49.6 ± 1.30 56.5 ± 0.52 
7.0 39.2 ± 0.94 48.6 ± 1.34 50.2 ± 1.07 52.3 ± 0.65 56.9 ± 0.22 
7.5 42.6 ± 0.58 50.8 ± 1.17 53.7 ± 0.94 57.0 ± 1.97 60.8 ± 1.89 
8.0 44.0 ± 1.16 53.1 ± 1.17 56.0 ± 1.95 61.4 ± 0.83 64.1 ± 0.52 
9.0 46.5 ± 1.28 54.7 ±  1.60 58.4 ± 0.96 65.8 ± 0.95 68.1 ± 1.29 
10.0 49.7 ± 1.19 59.1 ± 1.10 61.1 ± 1.15 67.0 ± 0.19 71.4 ± 2.39 
11.0 52.1 ± 0.02 60.7 ± 1.00 63.2 ± 1.98 69.6 ± 1.05 74.9 ± 1.39 
12.0 54.5 ± 0.65 63.8 ± 1.50 66.7 ± 1.57 70.8 ± 1.39 79.9 ± 0.70 
n=3* 
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    COMPARISON OF INVITRO RELEASE OF RAMIPRIL NIOSOMES 
 
TIME IN HOURS 
CUMULATIVE % DRUG RELLEASE ± SD* 
F6(SPAN 60 1:6) F7(SPAN 20 1:1) F8(SPAN 40 1:1) F9(SPAN80 1:1) F10(TWEEN60 1:1) 
0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
0.25 0 ± 0 5.0 ± 0.42 4 ± 0.51 4.1 ± 0.80 4.6 ±0.22 
0.5 0 ±0 7.0 ± 0.69 5.9 ± 1.51 6.2 ± 1.18 6.8 ±1.49 
0.75 5.2 ±0 .99 10.6 ± 1.39 8.5 ± 1.16 8.2 ± 2.30 9.3 ±1.03 
1.0 8.3 ± 1.29 15.3 ± 1.14 11.6 ± 1.14 10.9 ± 1.65 14.0 ±1.09 
1.5 11.4 ± 0.59 19.5 ± 1.69 14.0 ± 1.72 15.0 ± 1.25 18.8 ±2.50 
2.0 14.6 ± 1.59 23.8 ± 0.59 17.0 ± 1.17 18.1 ± 1.53 23.3 ±1.34 
2.5 18.5 ± 1.69 28.4 ± 0.99 19.7 ± 1.16 21.0 ± 1.26 28.2 ±1.28 
3.0 22.3 ± 1.99 33.2 ± 0.71 23.7 ± 1.19 23.6 ± 1.98 32.0 ±1.29 
3.5 25.6 ± 2.39 36.5 ± 1.30 26.7 ±  1.00 26.0 ± 1.26 36.2 ±1.19 
4.0 28.9 ± 1.42 39.1 ± 1.32 30.0 ± 1.20 29.2 ± 1.04 40.8 ±1.34 
4.5 32.2 ± 2.21 42.2 ± 0.61 32.4 ± 1.23 32.1 ± 1.03 45.5 ±1.92 
5.0 35.9 ± 3.89 44.5 ± 0.91 34.3 ± 1.19 35.6 ± 2.01 49.9 ±1.27 
5.5 39.4 ± 2.89 48.7 ± 1.80 38.0 ± 1.15 38.7 ± 1.76 54.5 ±1.08 
6.0 42.1 ± 1.51 51.1 ± 1.48 40.5 ± 1.13 40.9 ± 1.26 57.7 ±1.25 
6.5 46.2 ± 1.21 53.9 ± 1.23 43.9 ± 1.86 43.8 ± 1.25 61.2 ±1.20 
7.0 48.9 ± 1.41 57.4 ± 2.01 46.8 ± 1.26 46.7 ±1.20 65.6 ±0.74 
7.5 51.8 ± 0.71 59.9 ± 1.74 49.5 ± 0.01 48.8 ±1.92 70.3 ±1.79 
8.0 53.7 ± 0.80 62.8 ± 0.94 51.5 ± 1.24 50.9 ±1.95 74.6 ±1.02 
9.0 56.4 ± 1.10 67.4 ± 1.17 52.7 ± 0.25 52.6 ±1.17 79.5 ±1.09 
10.0 58.9 ± 1.31 70.4 ± 2.11 55.5 ± 0.92 55.8 ±1.10 84.0 ±1.03 
11.0 62.7 ± 1.69 73.9 ± 1.16 58.8 ± 1.62 58.2 ±1.49 88.2 ±1.04 
12.0 65.4 ± 0.59 77.4 ± 1.18 61.4 ± 0.74 62.2 ±1.08 94.4 ±1.04 
 n=3* 
Table No: 12 
COMPARISON ON INVITRO RELEASE OF RAMIPRIL NIOSOMES (SPAN 60 1:1)                                                                  
WITH RAMIPRIL DRUG SOLUTION 
 
 
 
TIME IN HOURS 
 
CUMULATIVE % DRUG RELEASE±SD* 
 
F1 (SPAN 60 1:1)     PURE DRUG SOLUTION 
0 0 ± 0 0 ± 0 
0.25 0 ± 0 30.3 ± 0.83 
0.5 0 ± 0 43.3 ± 1.40 
0.75 0 ± 0 48.6 ± 1.31 
1.0 4.1 ± 0.24 54.9 ± 0.70 
1.5 7.7 ± 1.71 62.3 ± 1.69 
2.0 11.3 ± 1.75 68.1 ± 1.59 
2.5 15.9 ± 1.67 75.7 ± 1.49 
3.0 19.7 ± 2.54 85.8 ± 2.96 
3.5 24.5 ± 2.01 96.4 ± 2.78 
4.0 26.7 ± 1.76 97.3 ± 2.67 
4.5 29.3 ± 1.10 98.0 ± 1.08 
5.0 31.4 ± 1.95 98.7 ± 1.05 
5.5 33.9 ± 0.60 98.6 ± 1.13 
6.0 34.8 ± 0.40 97.6 ± 0.79 
6.5 37.2 ± 1.04 97.3 ± 0.45 
7.0 39.2 ± 0.94 97.3 ± 0.67 
7.5 42.6 ± 0.58 97.2 ± 1.56 
8.0 44.0 ± 1.16 97.1 ± 0.57 
9.0 46.5 ± 1.28 96.6 ± 0.94 
10.0 49.7 ± 1.19 96.3 ± 1.47 
11.0 52.1 ± 0.02 96.0 ± 1.18 
12.0 54.5 ± 0.65 95.7  ± 0.60 
 
           n=3*   
Table no: 13 
EFFECT OF SONICATION TIME (SPAN 60 1:1) 
 
 
 
  
  
  
 
 
 
  
  
     
 
 
 
 
 
 
 
Table no: 14 
EFFECT OF HYDRATION TIME (SPAN 60 1:1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
S.NO 
 
 
SONICATION TIME 
(MINUTES) 
 
% ENTRAPMENT 
EFFICIENCY 
 
1 
 
 
0 
 
35.90 
 
2 
 
 
1 
 
38.64 
 
3 
 
 
2 
 
38.92 
 
4 
 
 
3 
 
47.22 
 
5 
 
 
4 
 
42.51 
 
 
6 
 
 
5 
 
36.54 
 
S.NO 
 
HYDRATION TIME(MINUTES) % ENTRAPMENT EFFICIENCY 
 
1 
 
 
30 
 
35.22 
 
2 
 
 
45 
 
52.21 
 
3 
 
 
60 
 
41.63 
 
4 
 
 
75 
 
31.04 
5 
 
90 13.12 
      Table No: 15 
 
FORMULATION OF RAMIPRIL NIOSOMES WITH AND            
WITHOUT CHARGE INDUCING AGENTS.  
 
 
 
S.NO. 
 
 
 
FORMULATION 
  
SURFACTANT : 
CHOLESTEROL                      
(1:1 MOLAR RATIO) 
 
CHARGE INDUCING 
AGENTS 
  
STR DCP 
 
1. 
 
 
F1 
 
 
30 µmol 
 
-- 
 
-- 
 
2. 
 
 
F11 
 
 
30 µmol 
 
5 µmol 
 
-- 
 
3. 
 
 
F12 
 
 
30 µmol 
 
-- 
 
10 µmol 
 
4. 
 
 
F13 
 
 
30 µmol 
 
-- 
 
5 µmol 
 
5. 
 
 
F14 
 
30 µmol 
 
-- 
 
15 µmol 
 
Drug concentration used in each formulation kept as constant 2.5mg/5ml.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table No: 16 
 
ENTRAPMENT EFFICIENCIES OF RAMIPRIL NIOSOMES                    
WITH AND WITHOUT CHARGE INDUCING AGENTS. 
 
 
 
S.NO 
 
FORMULATION 
 
% ENTRAPMENT EFFICIENCY ± SD* 
 
 
1. 
 
 
F1 
 
35.05±0.46 
 
2. 
 
 
F11 
 
40.53±0.33 
 
3. 
 
 
F12 
 
27.88±0.48 
 
4. 
 
 
F13 
 
20.45±0.88 
 
5. 
 
 
F14 
 
20.62±0.56 
 
      n=3* 
 
 
 
 
 
 
Table No: 17 
COMPARISON ON INVITRO RELEASE OF RAMIPRIL NIOSOMES (SPAN 60 1:1)                                                             
WITH AND WITHOUT CHARGE INDUCING AGENTS. 
 
 
TIME IN HOURS 
 
CUMULATIVE % DRUG RELEASE±SD* 
 
F1 F11(STR) F12(DCP) 
0 0 ± 0 0 ± 0 0 ± 0 
0.25 0 ± 0 1.10 ± 0.67 1.30 ± 1.51 
0.5 0 ± 0 2.30 ± 0.96 2.60 ± 1.21 
0.75 0 ± 0 3.90 ± 1.80 3.90 ± 0.80 
1.0 4.1 ± 0.24 5.50 ± 1.09 8.20± 1.02 
1.5 7.7 ± 1.71 8.30 ± 0.87 11.6 ± 0.98 
2.0 11.3 ± 1.75 12.2 ± 0.96 15.8 ± 1.80 
2.5 15.9 ± 1.67 14.6 ± 1.46 20.9 ± 1.53 
3.0 19.7 ± 2.54 17.3 ± 1.07 23.8 ± 2.02 
3.5 24.5 ± 2.01 19.5 ± 2.48 28.5 ± 1.40 
4.0 26.7 ± 1.76 20.5 ± 0.75 33.4 ± 1.54 
4.5 29.3 ± 1.10 22.6 ± 1.60 36.0 ± 1.72 
5.0 31.4 ± 1.95 24.5 ± 1.60 39.0 ± 1.65 
5.5 33.9 ± 0.60 27.8 ± 0.40 40.5 ± 0.96 
6.0 34.8 ± 0.40 32.1 ± 1.50 42.6 ± 0.47 
6.5 37.2 ± 1.04 35.7 ± 1.85 45.7 ± 1.18 
7.0 39.2 ± 0.94 39.2 ± 1.34 49.8 ± 1.07 
7.5 42.6 ± 0.58 42.2 ± 1.17 52.8 ± 0.94 
8.0 44.0 ± 1.16 45.4 ± 1.00 56.8 ± 1.95 
9.0 46.5 ± 1.28 49.0 ± 1.60 59.0 ± 0.96 
10.0 49.7 ± 1.19 52.8 ± 1.10 60.3 ± 1.15 
11.0 52.1 ± 0.02 55.3 ± 1.00 63.2 ± 1.98 
12.0 54.5 ± 0.65 58.5 ± 1.50 67.4 ± 1.57 
 
n=3*    STR- Stearylamine   DCP- Dicetyl phosphate. 
Table No: 18 
DETERMINATTION OF ORDER OF RELEASE OF RAMIPRIL FROM NIOSOMAL FORMULATIONS 
      
 
Formulation 
 
 
Higuchi 
 
r2 
Korsemeyer-
Peppas 
 
Zero order 
 
First order 
 
Hixson-Crowell 
 
Release 
mechanism 
r2 n r2 K0 (% 
mg/h) 
r2 K1 (h-1) r2 Slope (n) 
 
F1 
 
0.9945 
 
0.9581 
 
0.9853 
 
0.957 
 
4.997 
 
0.9885 
 
0.0306 
 
0.980 
 
0.0968 
 
NFD 
 
F2 
 
0.9926 
 
0.9697 
 
0.9533 
 
0.960 
 
5.800 
 
0.9926 
 
0.0392 
 
0.986 
 
0.1262 
 
NFD 
 
F3 
 
0.9945 
 
0.9777 
 
0.9108 
 
0.959 
 
6.007 
 
0.9938 
 
0.0418 
 
0.986 
 
0.1196 
 
NFD 
 
F4 
 
0.9869 
 
0.9796 
 
0.9369 
 
0.968 
 
6.559 
 
0.9882 
 
0.0487 
 
0.987 
 
0.1437 
 
NFD 
 
F5 
 
0.9969 
 
0.9749 
 
0.9301 
 
0.961 
 
7.066 
 
0.9971 
 
0.0572 
 
0.995 
 
0.1625 
 
NFD 
 
F6 
 
0.9917 
 
0.9906 
 
0.9066 
 
0.969 
 
5.921 
 
0.9954 
 
0.0405 
 
0.991 
 
0.1231 
 
NFD 
 
F7 
 
0.9974 
 
0.9939 
 
0.7280 
 
0.963 
 
6.401 
 
0.9984 
 
0.0522 
 
0.996 
 
0.1067 
 
NFD 
 
F8 
 
0.9897 
 
0.9967 
 
0.7341 
 
0.968 
 
5.206 
 
0.9935 
 
0.0350 
 
0.988 
 
0.1067 
 
NFD 
 
F9 
 
0.9916 
 
0.9977 
 
0.7284 
 
0.969 
 
5.188 
 
0.9951 
 
0.0350 
 
0.988 
 
0.1071 
 
NFD 
 
F10 
 
0.9876 
 
0.9972 
 
0.8157 
 
0.984 
 
8.003 
 
0.9409 
 
0.0876 
 
0.988 
 
0.2196 
 
NFD 
 
 NFD- NONFICKIAN DIFFUSION 
  
Table no: 19 
 
STABILITY STUDIES OF NIOSOMES CONTAINING SPAN 60 (1:1) 
 
 
 
S.NO 
 
WEEK 
% ENTRAPMENT EFFICIENCY 
AT 60% RH±5% RH 
 4±20C  25±20 C 
 
1. 
 
 
0 
 
35.05 
 
35.05 
 
2. 
 
 
1 
 
35.00 
 
34.54 
 
 
3. 
 
 
2 
 
34.88 
 
33.21 
 
4. 
 
 
3 
 
34.29 
 
32.44 
 
5. 
 
 
4 
 
33.81 
 
31.07 
 
 
         
Figure: 10 
DETERMINATION OF λ max OF RAMIPRIL IN PHOSPHATE BUFFERED SALINE PH- 7.4.
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         Figure- 11 
  CALIBRATION OF RAMIPRIL IN PBS (pH 7.4) AT λmax 207nm 
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Figure- 12 
COMPARISON OF ENTRAPMENT EFFICIENCIES OF RAMIPRIL NIOSOMES. 
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         Figure- 13 
COMPARISON OF INVITRO RELEASE OF RAMIPRIL NIOSOMES CONTAINING                                      
SPAN 60 AT DIFFERENT RATIOS. 
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 Figure- 14 
COMPARISON OF INVITRO RELEASE OF RAMIPRIL NIOSOMES                                                   
CONTAINING DIFFERENT SURFACTANTS AT 1:1 RATIO. 
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Figure: 15 a. 
PARTICLE SIZE DISTRIBUTION F1 
(SONICATION TIME= 0 MINUTES) 
                           
Figure: 15 b. 
PARTICLE SIZE DISTRIBUTION F1 
(SONICATION TIME= 1 MINUTE)
  
Figure: 15 c. 
       PARTICLE SIZE DISTRIBUTION F1 
(SONICATION TIME= 2 MINUTES) 
 
Figure: 15 d. 
PARTICLE SIZE DISTRIBUTION F1 
(SONICATION TIME= 3 MINUTES) 
 
Figure: 15 e. 
PARTICLE SIZE DISTRIBUTION F1 
(SONICATION TIME= 4 MINUTES) 
 
Figure: 15 f. 
PARTICLE SIZE DISTRIBUTION F1 
(SONICATION TIME= 5 MINUTES)
 
EFFECT OF OSMOTIC SHOCK 
                 [A]         
[B]     
[C]    
Figure: 16 [A] - HYPERTONIC (1.6% NaCl)    [B]- HYPOTONIC (0.5% NaCl)                                                                                               
[C]- ISOTONIC (0.9% NaCl) 
 
Figure- 17 
COMPARISON OF INVITRO RELEASE OF RAMIPRIL NIOSOME                                                    
SPAN 60 1:1 WITH AND WITHOUT CHARGE INDUCING AGENTS. 
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         Figure - 18 
COMPARISON OF INVITRO RELEASE OF RAMIPRIL DRUG SOLUTION,                                             
NIOSOME F1 (SPAN 60 1:1) AND F12 (WITH DCP). 
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Figure - 19 
COMPARISON OF INVITRO RELEASE STUDIES OF RAMIPRIL FORMULATIONS 
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Particle size distribution (F12) at Malvern zeta sizer.     
Figure : 20 a. 
 
Particle size distribution (F12) at Malvern zeta sizer.
Figure : 20 b. 
                 
 
Zeta potential mesurement (F12) at Malvern zeta sizer.
Figure : 21. 
 
 
                 
Figure: 22 
SEM Photograph of F1 
            
Figure: 23. FT-IR SPECTROSCOPY OF PURE DRUG- RAMIPRIL.
 
Figure: 24a. FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 20.
 
Figure: 24b.COMPARISON OF FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 20 WITH RAMIPRIL.
Figure: 25a. FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 40
Figure: 25b.  COMPARISON OF FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 40 WITH RAMIPRIL.
Figure: 26a. FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 60.
 
A)
 
B)
 
C)
 
D)
 
E)
 
F)
 
Figure: 28. DSC thermograms are as follows, A) Ramipril; B) Cholesterol; C) Span 40; D) Span 
60; E) Formulation containing Span 40 and F) Formulation containing Span 60. 
Figure : 29. 
STABILITY STUDIES OF RAMIPRIL NIOSOMES AT TWO DIFFERENT TEMPERATURES. 
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